ClinicaPublication

Home › Books › DNB Dermatology › Previous-year questions

Free question list · June 2020 to December 2025

DNB Dermatology, Venereology & Leprosy previous-year questions (2020–2025)

All 500 DNB Dermatology theory questions from June 2020 to December 2025, topic-wise and session-wise, with how often each one has been asked. Use the list to find the high-yield topics, then read the solved answers in our printed book.

Get the solved bookRead free sample (PDF)

Most-asked DNB Dermatology questions

These questions have been set three times or more since June 2020. The number shows how many times each was asked.

  1. Congenital syphilis: clinical features, diagnosis & management 7×Volume 3 · Part 17 · Genital Anatomy and Sexually Transmitted Infections
  2. Hair restoration surgery: evaluation & techniques (FUT/FUE) 7×Volume 3 · Part 21 · Dermatosurgery and Lasers
  3. Nail apparatus: diagram, development, parts & functions 6×Volume 1 · Part 1 · Structure and Function of the Skin and Appendages
  4. Wound healing: principles/stages, abnormal healing & newer therapies 6×Volume 1 · Part 2 · Immunology, Physiology, Photobiology and Genetics
  5. Itch: neurophysiology, mediators & anti-itch agents 6×Volume 1 · Part 2 · Immunology, Physiology, Photobiology and Genetics
  6. JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis) 6×Volume 1 · Part 5 · Biologics, Small Molecules, Newer Drugs and Phototherapy
  7. DRESS: diagnosis (RegiSCAR) & management 6×Volume 2 · Part 8 · Urticaria, Drug Reactions and Mastocytosis
  8. Bacterial vaginosis: diagnosis (Amsel, Nugent, clue cells) & complications 6×Volume 3 · Part 17 · Genital Anatomy and Sexually Transmitted Infections
  9. Interface dermatitis & lichenoid tissue reaction 5×Volume 1 · Part 3 · Dermatopathology and Diagnostic Techniques
  10. Skin biopsy: indications, techniques & fixatives 5×Volume 1 · Part 3 · Dermatopathology and Diagnostic Techniques
  11. Autoantibodies & ANA in connective tissue diseases 5×Volume 2 · Part 9 · Bullous and Connective Tissue Diseases
  12. Melasma: aetiology, management & recent advances 5×Volume 2 · Part 11 · Pigmentary, Hair, Nail and Adnexal Disorders
  13. Hidradenitis suppurativa: pathogenesis, staging, complications & management 5×Volume 2 · Part 11 · Pigmentary, Hair, Nail and Adnexal Disorders
  14. Hirsutism & hyperandrogenism: causes, evaluation & treatment 5×Volume 2 · Part 11 · Pigmentary, Hair, Nail and Adnexal Disorders
  15. Cutaneous amyloidosis 5×Volume 2 · Part 13 · Genetic, Metabolic and Nutritional Disorders; Skin in Systemic Disease
  16. Complications of gonorrhoea 5×Volume 3 · Part 17 · Genital Anatomy and Sexually Transmitted Infections
  17. PPNG & antimicrobial resistance in gonorrhoea 5×Volume 3 · Part 17 · Genital Anatomy and Sexually Transmitted Infections
  18. Child sexual abuse, POCSO Act & STI evaluation in children 5×Volume 3 · Part 18 · Syndromic Management, HIV and STI Programmes
  19. Relapse in leprosy (definition, causes, diagnosis, relapse vs reaction) 5×Volume 3 · Part 20 · Leprosy: Reactions, Neuritis, Treatment, Disability and Programme
  20. Trophic ulcer, foot care & care of anaesthetic hands/feet 5×Volume 3 · Part 20 · Leprosy: Reactions, Neuritis, Treatment, Disability and Programme
  21. Sutures & suturing techniques 5×Volume 3 · Part 21 · Dermatosurgery and Lasers
  22. Artificial intelligence in dermatology 5×Volume 3 · Part 23 · Recent Advances: AI, Teledermatology and COVID-19
  23. Dermo-epidermal junction / basement membrane zone: labelled diagram 4×Volume 1 · Part 1 · Structure and Function of the Skin and Appendages
  24. Hair cycle (diagram) & factors affecting it 4×Volume 1 · Part 1 · Structure and Function of the Skin and Appendages

Topic-wise DNB Dermatology previous-year questions

Grouped the way the book is organised, 3 volumes and 23 parts. Open a part to see its questions, how often each was asked, and the session, paper, question number and marks.

Volume 1 — Basic Science, Diagnostics & Therapeutics

Part 1 · Structure and Function of the Skin and Appendages23 questions
  1. Keratinization: keratins & cornified cell envelope 2×Jun 2021 · Paper I · Q6 (10 marks) · Jun 2022 · Paper I · Q1 (10 marks)
  2. Dermo-epidermal junction / basement membrane zone: labelled diagram 4×Jun 2020 · Paper I · Q1(a) (5 marks) · Dec 2020 · Paper I · Q1(a) (5 marks) · Oct 2023 · Paper I · Q9(a) (5 marks) · May 2024 · Paper I · Q7(a) (2 marks)
  3. Desmosomes, cell junctions & desmosomal diseases 3×Jun 2021 · Paper I · Q3(a) (5 marks) · Dec 2022 · Paper I · Q1 (10 marks) · Apr 2023 · Paper I · Q7(a) (5 marks)
  4. Dermis: cells, fibres & extracellular matrix 1×Jun 2022 · Paper I · Q4 (10 marks)
  5. Collagen synthesis 1×Dec 2025 · Paper I · Q2(b) (5 marks)
  6. Skin barrier: structure, function & impaired barrier 2×Dec 2021 · Paper I · Q1 (10 marks) · Oct 2023 · Paper I · Q2 (10 marks)
  7. Melanogenesis & its regulation 3×Jun 2021 · Paper I · Q9(b) (5 marks) · Dec 2021 · Paper I · Q4(a) (4 marks) · May 2024 · Paper I · Q8(a) (6 marks)
  8. Epidermal melanin unit 2×Jun 2021 · Paper I · Q9(a) (5 marks) · Dec 2021 · Paper I · Q4(b) (3 marks)
  9. Epidermal vs follicular melanocytes 1×Jun 2022 · Paper I · Q9(a) (3 marks)
  10. Eumelanin & melanin types 1×Dec 2025 · Paper I · Q5(b) (5 marks)
  11. Hair cycle (diagram) & factors affecting it 4×Jun 2020 · Paper I · Q2(a) (5 marks) · Dec 2022 · Paper I · Q5(a) (4 marks) · Apr 2023 · Paper I · Q1(a) (5 marks) · Oct 2023 · Paper I · Q9(b) (5 marks)
  12. Hair keratins, hair colour & colouring agents 2×Dec 2022 · Paper I · Q5(b) (3 marks) · Dec 2022 · Paper I · Q5(c) (3 marks)
  13. Hair follicle: longitudinal section (diagram) 1×Oct 2024 · Paper I · Q4(a) (5 marks)
  14. Nail apparatus: diagram, development, parts & functions 6×Jun 2021 · Paper I · Q10(a) (5 marks) · Jun 2021 · Paper I · Q10(b) (5 marks) · Dec 2021 · Paper I · Q2(a) (3 marks) · May 2024 · Paper I · Q5(a) (6 marks) · Jun 2025 · Paper I · Q4(a) (3 marks) · Jun 2025 · Paper I · Q4(b) (3 marks)
  15. Hyperhidrosis: primary & management 3×Jun 2021 · Paper I · Q1(c) (5 marks) · Dec 2021 · Paper II · Q5(a) (3 marks) · Dec 2022 · Paper IV · Q4(a) (5 marks)
  16. Sweat glands (eccrine & apocrine): structure & function 4×Jun 2021 · Paper I · Q1(a) (3 marks) · Oct 2023 · Paper I · Q1 (10 marks) · Oct 2024 · Paper I · Q1(a) (3 marks) · Oct 2024 · Paper I · Q1(b) (3 marks)
  17. Sweat function tests 2×Jun 2021 · Paper I · Q1(b) (2 marks) · Oct 2024 · Paper I · Q7(b) (4 marks)
  18. Fox Fordyce disease 1×Oct 2024 · Paper I · Q1(c) (4 marks)
  19. Pilosebaceous unit, sebum composition & sebaceous gland disorders 1×Jun 2020 · Paper I · Q4 (10 marks)
  20. Skin ageing: intrinsic & extrinsic 3×Jun 2022 · Paper IV · Q6(c) (4 marks) · May 2024 · Paper I · Q3 (10 marks) · Jun 2025 · Paper I · Q6(a) (5 marks)
  21. Histology of normal oral mucosa 1×Dec 2020 · Paper I · Q4(a) (4 marks)
  22. Muscles of facial expression & innervation 1×Dec 2022 · Paper I · Q3(a) (5 marks)
  23. Sensory innervation of hand & foot 1×Apr 2023 · Paper I · Q9(a) (5 marks)
Part 2 · Immunology, Physiology, Photobiology and Genetics32 questions
  1. Antimicrobial peptides 3×Dec 2020 · Paper I · Q6(a) (3 marks) · Dec 2022 · Paper I · Q3(b) (3 marks) · May 2024 · Paper I · Q4 (10 marks)
  2. Toll-like receptors & innate immunity 3×Jun 2021 · Paper I · Q2(a) (5 marks) · Oct 2023 · Paper I · Q10(b) (5 marks) · Dec 2025 · Paper I · Q2(a) (5 marks)
  3. Regulatory T cells & resident memory T cells 3×Jun 2021 · Paper I · Q2(b) (5 marks) · May 2024 · Paper I · Q2(a) (5 marks) · May 2024 · Paper I · Q2(b) (5 marks)
  4. Adhesion molecules 1×Dec 2020 · Paper I · Q6(c) (4 marks)
  5. Langerhans cells, dendritic cells & antigen-presenting cells 3×Jun 2021 · Paper I · Q8(b) (5 marks) · Oct 2024 · Paper I · Q2 (10 marks) · Jun 2025 · Paper I · Q1(a) (5 marks)
  6. Mast cells 2×Dec 2020 · Paper I · Q6(b) (3 marks) · Oct 2024 · Paper I · Q10(a) (3 marks)
  7. Skin immune network: dendritic cells, mast cells & macrophages 1×Jun 2022 · Paper I · Q8 (10 marks)
  8. Merkel cells 1×Jun 2025 · Paper I · Q1(b) (5 marks)
  9. Plasma cells 1×Dec 2025 · Paper I · Q10(b) (5 marks)
  10. Cutaneous stem cells: properties, types & role 4×Dec 2020 · Paper I · Q2 (10 marks) · Jun 2022 · Paper I · Q5 (10 marks) · Dec 2022 · Paper I · Q4(a) (4 marks) · Dec 2025 · Paper I · Q5(a) (5 marks)
  11. Stem cell based therapies 3×Jun 2021 · Paper I · Q3(b) (5 marks) · Dec 2022 · Paper I · Q4(b) (3 marks) · May 2024 · Paper IV · Q9(a) (3 marks)
  12. Gene therapy & gene editing 2×Dec 2022 · Paper I · Q4(c) (3 marks) · May 2024 · Paper IV · Q7(b) (3 marks)
  13. Wound healing: principles/stages, abnormal healing & newer therapies 6×Jun 2020 · Paper I · Q8 (10 marks) · Dec 2020 · Paper I · Q8 (10 marks) · Jun 2022 · Paper I · Q2 (10 marks) · Apr 2023 · Paper I · Q3(a) (5 marks) · Apr 2023 · Paper I · Q3(b) (5 marks) · Dec 2025 · Paper I · Q4 (10 marks)
  14. Skin substitutes in wound care 1×May 2024 · Paper IV · Q7(a) (4 marks)
  15. Itch: neurophysiology, mediators & anti-itch agents 6×Dec 2020 · Paper I · Q7(a) (6 marks) · Dec 2020 · Paper I · Q7(b) (4 marks) · Oct 2023 · Paper I · Q4 (10 marks) · May 2024 · Paper I · Q1(b) (6 marks) · Oct 2024 · Paper I · Q8(a) (5 marks) · Dec 2025 · Paper I · Q7(a) (6 marks)
  16. Pruritus: clinical types & senile pruritus 2×May 2024 · Paper I · Q1(a) (2 marks) · May 2024 · Paper I · Q1(c) (2 marks)
  17. Management of pruritus 1×Oct 2024 · Paper I · Q8(b) (5 marks)
  18. Skin as an endocrine organ 2×Dec 2020 · Paper I · Q5(a) (6 marks) · Dec 2025 · Paper I · Q3 (10 marks)
  19. Vitamin D synthesis in skin 1×Dec 2020 · Paper I · Q5(b) (4 marks)
  20. Skin as a thermoregulatory organ 1×May 2024 · Paper I · Q10(a) (4 marks)
  21. Effects of UV radiation on skin 3×Dec 2021 · Paper I · Q10(a) (3 marks) · Oct 2024 · Paper II · Q5(b) (3 marks) · Jun 2025 · Paper I · Q9(b) (5 marks)
  22. Solar / UV spectrum, sources & measurement 3×May 2024 · Paper I · Q10(b) (3 marks) · Oct 2024 · Paper II · Q5(a) (2 marks) · Jun 2025 · Paper I · Q9(a) (5 marks)
  23. Sunscreens & sun protection factor (SPF) 2×Apr 2023 · Paper I · Q4(a) (5 marks) · Dec 2025 · Paper I · Q8(b) (5 marks)
  24. Fitzpatrick skin phototypes 1×Dec 2021 · Paper I · Q10(c) (3 marks)
  25. Skin microbiome & normal flora (site-specific) 4×Jun 2021 · Paper I · Q8(a) (5 marks) · Dec 2021 · Paper I · Q5(a) (4 marks) · Oct 2023 · Paper I · Q3 (10 marks) · Dec 2025 · Paper I · Q1 (10 marks)
  26. Biofilms in skin disease 2×Dec 2021 · Paper I · Q5(c) (3 marks) · Oct 2023 · Paper II · Q6(b) (5 marks)
  27. Cutaneous mosaicism 4×Jun 2020 · Paper I · Q10(a) (5 marks) · Jun 2022 · Paper I · Q9(c) (3 marks) · Oct 2023 · Paper I · Q8(a) (5 marks) · Dec 2025 · Paper I · Q10(a) (5 marks)
  28. Pigmentary demarcation lines & linear lesions 2×Jun 2020 · Paper I · Q10(b) (5 marks) · Oct 2023 · Paper I · Q8(b) (5 marks)
  29. Prenatal diagnosis of genodermatoses 2×Dec 2020 · Paper I · Q9(a) (4 marks) · May 2024 · Paper I · Q7(c) (5 marks)
  30. Patterns of inheritance & genome sequencing 1×Jun 2022 · Paper I · Q3 (10 marks)
  31. Primary & secondary skin lesions; configuration & distribution 2×Jun 2022 · Paper I · Q10 (10 marks) · Jun 2025 · Paper I · Q3 (10 marks)
  32. Koebner (isomorphic) phenomenon 1×Jun 2020 · Paper I · Q7 (10 marks)
Part 3 · Dermatopathology and Diagnostic Techniques28 questions
  1. Interface dermatitis & lichenoid tissue reaction 5×Jun 2020 · Paper I · Q9(a) (6 marks) · Jun 2020 · Paper I · Q9(b) (4 marks) · Oct 2023 · Paper I · Q10(a) (5 marks) · May 2024 · Paper I · Q6(a) (6 marks) · Oct 2024 · Paper I · Q5(b) (4 marks)
  2. Grenz zone 2×Oct 2023 · Paper II · Q5(a) (5 marks) · Dec 2025 · Paper I · Q8(a) (5 marks)
  3. Dermal deposition disorders (histopathology) 1×Dec 2022 · Paper I · Q7(a) (4 marks)
  4. Pseudoepitheliomatous & psoriasiform hyperplasia 2×Dec 2022 · Paper I · Q7(b) (3 marks) · Dec 2022 · Paper I · Q7(c) (3 marks)
  5. Cutaneous tissue reaction patterns (overview) 1×Oct 2024 · Paper I · Q5(a) (6 marks)
  6. Spongiotic reaction pattern 1×Dec 2025 · Paper I · Q9(a) (5 marks)
  7. Special stains (incl. PAS) in dermatopathology 3×Jun 2021 · Paper I · Q7(b) (5 marks) · Oct 2023 · Paper I · Q7(b) (5 marks) · Dec 2025 · Paper I · Q9(b) (5 marks)
  8. Immunohistochemistry in dermatology 3×Dec 2021 · Paper I · Q7(b) (4 marks) · Oct 2023 · Paper I · Q5(b) (5 marks) · May 2024 · Paper IV · Q5(b) (4 marks)
  9. Immunofluorescence: techniques & uses 1×Jun 2021 · Paper IV · Q9 (10 marks)
  10. Electron microscopy in skin diseases 1×Apr 2023 · Paper I · Q9(b) (5 marks)
  11. Skin biopsy: indications, techniques & fixatives 5×Jun 2021 · Paper IV · Q3(a) (4 marks) · Jun 2021 · Paper IV · Q3(b) (6 marks) · Dec 2022 · Paper I · Q6(a) (3 marks) · May 2024 · Paper IV · Q4(d) (3 marks) · Jun 2025 · Paper I · Q2 (10 marks)
  12. Wood's lamp 3×Jun 2021 · Paper I · Q4(b) (5 marks) · Dec 2022 · Paper I · Q6(c) (3 marks) · May 2024 · Paper IV · Q5(c) (3 marks)
  13. Confocal microscopy (reflectance / ex-vivo) 2×Jun 2020 · Paper I · Q3(b) (5 marks) · May 2024 · Paper IV · Q1(a) (3 marks)
  14. Tzanck smear & cytodiagnosis 2×Jun 2021 · Paper I · Q7(a) (5 marks) · Oct 2023 · Paper I · Q5(a) (5 marks)
  15. Dark field microscopy 1×Jun 2020 · Paper I · Q3(a) (5 marks)
  16. High-frequency ultrasound 1×Jun 2021 · Paper IV · Q10(b) (5 marks)
  17. Intradermal tests 1×Dec 2022 · Paper I · Q6(b) (4 marks)
  18. Trichoscopy in hair shaft disorders 2×Jun 2020 · Paper I · Q2(b) (5 marks) · Dec 2020 · Paper I · Q10(a) (4 marks)
  19. Dermoscopy of lichen planus 2×Dec 2020 · Paper IV · Q10(a) (3 marks) · Apr 2023 · Paper I · Q10(b) (6 marks)
  20. Dermoscopy of pigmentary disorders (incl. exogenous ochronosis) 2×Dec 2021 · Paper I · Q9(c) (3 marks) · Jun 2025 · Paper II · Q2(a) (6 marks)
  21. Dermoscopy of tumours (BCC, melanocytic lesions, vascular structures) 3×Dec 2021 · Paper I · Q9(a) (4 marks) · Dec 2022 · Paper I · Q2(a) (5 marks) · Dec 2022 · Paper I · Q2(b) (5 marks)
  22. Trichoscopy of scarring alopecias (LPP, DLE) 2×Oct 2023 · Paper II · Q7(a) (5 marks) · May 2024 · Paper I · Q9(b) (4 marks)
  23. Dermoscopy of psoriasis 1×Dec 2020 · Paper IV · Q10(c) (3 marks)
  24. Dermoscopy of vitiligo 1×Dec 2020 · Paper IV · Q10(b) (4 marks)
  25. Trichoscopy of alopecia areata 1×Jun 2021 · Paper I · Q5(b) (4 marks)
  26. Trichoscopy of tinea capitis 1×Dec 2021 · Paper I · Q9(b) (3 marks)
  27. Onychoscopy (dermoscopy of onychomycosis) 1×May 2024 · Paper IV · Q7(c) (3 marks)
  28. Ultraviolet-fluorescence dermoscopy 1×Jun 2025 · Paper IV · Q10(a) (4 marks)
Part 4 · Topical and Systemic Therapeutics25 questions
  1. Calamine lotion & gentian violet 2×Dec 2020 · Paper IV · Q3(b) (5 marks) · Jun 2021 · Paper IV · Q1(b) (3 marks)
  2. Topical drug delivery: absorption, vehicles, enhancers & novel systems 4×Jun 2022 · Paper I · Q7 (10 marks) · Jun 2025 · Paper I · Q7(a) (4 marks) · Jun 2025 · Paper I · Q7(b) (3 marks) · Jun 2025 · Paper I · Q7(c) (3 marks)
  3. Topical amphotericin B 1×Dec 2021 · Paper IV · Q7(b) (3 marks)
  4. Nail lacquers 1×Apr 2023 · Paper IV · Q6(a) (4 marks)
  5. Topical vehicles & fingertip unit 2×Apr 2023 · Paper I · Q8(a) (6 marks) · Apr 2023 · Paper I · Q8(b) (4 marks)
  6. Iontophoresis 1×Jun 2025 · Paper I · Q10(a) (5 marks)
  7. Systemic corticosteroids: regimens & indications 2×Dec 2020 · Paper IV · Q6(a) (5 marks) · Jun 2025 · Paper I · Q5(a) (5 marks)
  8. Systemic steroid adverse effects (osteoporosis) 1×Apr 2023 · Paper IV · Q3(a) (6 marks)
  9. Topical corticosteroids: classification 1×Jun 2025 · Paper I · Q5(b) (5 marks)
  10. Dexamethasone cyclophosphamide pulse (DCP) therapy 1×Dec 2025 · Paper II · Q1 (10 marks)
  11. Topical steroid misuse & topical steroid-dependent face 1×Dec 2025 · Paper IV · Q10(a) (5 marks)
  12. Methotrexate (use & monitoring) 2×Dec 2020 · Paper II · Q9(b) (6 marks) · Dec 2022 · Paper IV · Q10(a) (5 marks)
  13. Azathioprine 1×Dec 2020 · Paper IV · Q6(b) (5 marks)
  14. Therapeutic paradox in dermatology 1×Dec 2020 · Paper IV · Q7(b) (5 marks)
  15. Antioxidants in dermatology 1×Jun 2021 · Paper IV · Q8 (10 marks)
  16. Leflunomide 1×Dec 2021 · Paper IV · Q10(a) (3 marks)
  17. Newer antihistamines 1×Dec 2021 · Paper IV · Q5(a) (4 marks)
  18. Antimalarials in dermatology 1×Apr 2023 · Paper I · Q4(b) (5 marks)
  19. Ivermectin 1×Oct 2023 · Paper IV · Q4 (10 marks)
  20. Pentoxifylline 1×Oct 2023 · Paper IV · Q10(b) (5 marks)
  21. Lenalidomide 1×May 2024 · Paper IV · Q2(a) (3 marks)
  22. Opioid modulators: naltrexone & butorphanol 2×May 2024 · Paper IV · Q2(b) (4 marks) · May 2024 · Paper IV · Q2(c) (3 marks)
  23. Intravenous immunoglobulin (IVIG) 1×Jun 2025 · Paper I · Q10(b) (5 marks)
  24. Retinoids: classification, topical retinoids & prescribing guidelines 2×Dec 2021 · Paper IV · Q7(a) (4 marks) · Oct 2024 · Paper IV · Q10 (10 marks)
  25. Retinoids: monitoring & teratogenicity 2×Dec 2022 · Paper IV · Q10(b) (5 marks) · Apr 2023 · Paper IV · Q3(b) (4 marks)
Part 5 · Biologics, Small Molecules, Newer Drugs and Phototherapy16 questions
  1. IL-17 & IL-23 inhibitors (secukinumab, tildrakizumab) 2×Dec 2021 · Paper IV · Q10(b) (4 marks) · Oct 2023 · Paper IV · Q7(b) (3 marks)
  2. Rituximab: uses & work-up 2×Jun 2022 · Paper IV · Q2(b) (4 marks) · Apr 2023 · Paper II · Q3(b) (5 marks)
  3. Anakinra (IL-1 blockade) 1×Jun 2025 · Paper IV · Q7(c) (3 marks)
  4. CAR T-cell therapy 1×Jun 2025 · Paper IV · Q8(a) (5 marks)
  5. Nemolizumab (anti-IL-31) 1×Dec 2025 · Paper IV · Q2(a) (5 marks)
  6. JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis) 6×Dec 2020 · Paper IV · Q3(a) (5 marks) · Jun 2022 · Paper IV · Q2(a) (3 marks) · Dec 2022 · Paper IV · Q8(b) (3 marks) · May 2024 · Paper IV · Q3 (10 marks) · Jun 2025 · Paper IV · Q1 (10 marks) · Dec 2025 · Paper IV · Q2(b) (5 marks)
  7. Apremilast & PDE4 inhibitors 3×Dec 2021 · Paper IV · Q5(b) (3 marks) · Dec 2022 · Paper IV · Q8(a) (3 marks) · Dec 2025 · Paper IV · Q10(b) (5 marks)
  8. Bruton's tyrosine kinase (BTK) inhibitors 1×Jun 2025 · Paper IV · Q9(c) (4 marks)
  9. Ozenoxacin 2×Jun 2021 · Paper IV · Q1(a) (3 marks) · Jun 2025 · Paper IV · Q7(b) (4 marks)
  10. Trifarotene 2×Dec 2021 · Paper IV · Q10(c) (3 marks) · Oct 2023 · Paper IV · Q2(c) (3 marks)
  11. Antifibrotics: nintedanib & topical pirfenidone 2×Oct 2023 · Paper IV · Q7(a) (4 marks) · Dec 2025 · Paper IV · Q3(a) (3 marks)
  12. Oral minoxidil 2×Oct 2023 · Paper IV · Q7(c) (3 marks) · Dec 2025 · Paper IV · Q1(b) (5 marks)
  13. Berdazimer gel 1×Jun 2025 · Paper IV · Q7(a) (3 marks)
  14. mTOR inhibitors 1×Dec 2025 · Paper IV · Q5(b) (5 marks)
  15. Phototherapy: principles, dosing & NB-UVB 2×Dec 2022 · Paper II · Q6(c) (4 marks) · Dec 2025 · Paper I · Q7(b) (4 marks)
  16. Extracorporeal photopheresis 1×Oct 2023 · Paper I · Q6 (10 marks)
Part 6 · Severity Scores, Research Methods and Emergency Care6 questions
  1. PASI & disease severity scoring indices 3×Jun 2020 · Paper II · Q2(b) (3 marks) · Dec 2020 · Paper IV · Q8(a) (7 marks) · Dec 2020 · Paper IV · Q8(b) (3 marks)
  2. Quality-of-life indices (DLQI etc.) 2×Jun 2020 · Paper II · Q2(a) (7 marks) · Dec 2020 · Paper IV · Q7(a) (5 marks)
  3. Case-control vs cohort study, sample size & sampling methods 2×Jun 2020 · Paper I · Q6 (10 marks) · Dec 2020 · Paper I · Q3 (10 marks)
  4. Impact factor & Indian dermatology journals 2×Jun 2021 · Paper IV · Q10(a) (5 marks) · Dec 2021 · Paper IV · Q4(c) (3 marks)
  5. Systematic review, meta-analysis, levels of evidence & EBM 3×Dec 2021 · Paper IV · Q4(a) (4 marks) · Dec 2021 · Paper IV · Q4(b) (3 marks) · Jun 2022 · Paper IV · Q9(a) (2 marks)
  6. Basic & advanced cardiac life support (BLS/ACLS) 1×Dec 2022 · Paper I · Q10(a) (4 marks)

Volume 2 — Clinical Dermatology

Part 7 · Papulosquamous and Eczematous Disorders21 questions
  1. Psoriatic arthritis: classification (CASPAR) & management 3×Dec 2021 · Paper II · Q8(c) (3 marks) · Jun 2022 · Paper II · Q8(a) (4 marks) · Apr 2023 · Paper II · Q1(b) (6 marks)
  2. Biologics in psoriasis 2×Dec 2020 · Paper II · Q9(a) (4 marks) · Oct 2024 · Paper IV · Q2(b) (5 marks)
  3. Erythrodermic psoriasis (incl. children) 2×Dec 2020 · Paper II · Q6(b) (6 marks) · Dec 2021 · Paper II · Q8(a) (4 marks)
  4. Childhood psoriasis 1×Dec 2021 · Paper II · Q8(b) (3 marks)
  5. Severity scoring in psoriasis (nail, pustular, PsA) 1×Dec 2022 · Paper II · Q2 (10 marks)
  6. Pustular psoriasis 1×Apr 2023 · Paper II · Q1(a) (4 marks)
  7. Psoriasis: molecular etiopathogenesis 1×Oct 2024 · Paper IV · Q2(a) (5 marks)
  8. Keratosis lichenoides chronica 1×Dec 2025 · Paper II · Q2(b) (4 marks)
  9. Lichenoid drug eruptions 1×Dec 2025 · Paper II · Q2(a) (6 marks)
  10. Dupilumab & biologics in atopic dermatitis 3×Jun 2020 · Paper IV · Q8(b) (4 marks) · Oct 2023 · Paper II · Q3(a) (5 marks) · May 2024 · Paper II · Q4(b) (2 marks)
  11. Atopic dermatitis: diagnostic criteria & severity scoring 2×Jun 2022 · Paper II · Q2(a) (4 marks) · Oct 2024 · Paper IV · Q3(a) (5 marks)
  12. Atopic dermatitis: management (severe/childhood, pruritus) 2×Jun 2022 · Paper II · Q2(b) (6 marks) · Oct 2024 · Paper IV · Q3(b) (5 marks)
  13. Atopic dermatitis: aetiology 1×Dec 2022 · Paper II · Q9(b) (2 marks)
  14. Patch test & photopatch test 4×Dec 2020 · Paper I · Q10(b) (3 marks) · Jun 2021 · Paper II · Q1(b) (5 marks) · Dec 2022 · Paper II · Q6(a) (3 marks) · Jun 2025 · Paper I · Q8(b) (5 marks)
  15. Systemic contact dermatitis 2×Jun 2021 · Paper II · Q1(a) (5 marks) · Oct 2023 · Paper II · Q3(b) (5 marks)
  16. Occupational & footwear contact dermatitis 2×Jun 2022 · Paper II · Q9(a) (5 marks) · Apr 2023 · Paper II · Q8(a) (5 marks)
  17. Allergic contact dermatitis: pathophysiology 1×Jun 2020 · Paper I · Q5(a) (5 marks)
  18. Non-eczematous forms of allergic contact dermatitis 1×Jun 2020 · Paper I · Q5(b) (5 marks)
  19. Allergic vs irritant contact dermatitis 1×Jun 2025 · Paper I · Q8(a) (5 marks)
  20. Red face 1×Jun 2022 · Paper II · Q10(a) (3 marks)
  21. Perioral, periorbital & scrotal dermatitis 1×Jun 2025 · Paper II · Q3 (10 marks)
Part 8 · Urticaria, Drug Reactions and Mastocytosis16 questions
  1. Angioedema without wheals: hereditary & drug-induced 3×Jun 2020 · Paper II · Q6 (10 marks) · Jun 2022 · Paper II · Q8(b) (3 marks) · Jun 2025 · Paper II · Q9(a) (4 marks)
  2. Chronic spontaneous urticaria: investigations & management 3×Jun 2021 · Paper II · Q3(b) (5 marks) · Oct 2024 · Paper II · Q3(c) (4 marks) · Dec 2025 · Paper II · Q3(a) (4 marks)
  3. Physical / inducible urticarias (incl. cholinergic) 3×Jun 2021 · Paper II · Q3(a) (5 marks) · Oct 2024 · Paper II · Q3(b) (3 marks) · Dec 2025 · Paper II · Q3(c) (3 marks)
  4. Urticaria: classification 1×Oct 2024 · Paper II · Q3(a) (3 marks)
  5. Autologous serum therapy 1×Jun 2025 · Paper IV · Q8(b) (5 marks)
  6. Urticaria in pregnancy 1×Dec 2025 · Paper II · Q3(b) (3 marks)
  7. Mastocytosis: classification & management 3×Jun 2021 · Paper II · Q10 (10 marks) · Jun 2022 · Paper II · Q8(c) (3 marks) · Oct 2024 · Paper I · Q10(b) (3 marks)
  8. Telangiectasia macularis eruptiva perstans 1×Oct 2024 · Paper I · Q10(c) (4 marks)
  9. DRESS: diagnosis (RegiSCAR) & management 6×Jun 2020 · Paper IV · Q6(b) (5 marks) · Jun 2021 · Paper II · Q2(b) (7 marks) · Dec 2021 · Paper II · Q10(c) (3 marks) · Oct 2023 · Paper III · Q8(b) (5 marks) · Oct 2024 · Paper II · Q6(a) (5 marks) · Oct 2024 · Paper II · Q6(b) (5 marks)
  10. SJS/TEN: management & SCORTEN 3×Dec 2020 · Paper II · Q4(b) (5 marks) · Dec 2021 · Paper II · Q10(a) (4 marks) · Apr 2023 · Paper IV · Q7(b) (6 marks)
  11. Mechanisms of drug reactions & role of HLA 2×Jun 2020 · Paper IV · Q6(a) (5 marks) · Dec 2022 · Paper I · Q8(a) (5 marks)
  12. SCARs: definition & classification 2×Jun 2021 · Paper II · Q2(a) (3 marks) · Apr 2023 · Paper IV · Q7(a) (4 marks)
  13. Drug-induced autoimmune bullous diseases 2×May 2024 · Paper IV · Q9(b) (4 marks) · Jun 2025 · Paper II · Q9(b) (6 marks)
  14. Drug provocation test 1×Dec 2020 · Paper II · Q4(a) (5 marks)
  15. SDRIFE 1×Dec 2021 · Paper II · Q10(b) (3 marks)
  16. Cutaneous adverse effects of targeted anticancer therapy 1×May 2024 · Paper II · Q5(b) (5 marks)
Part 9 · Bullous and Connective Tissue Diseases22 questions
  1. Pemphigus & AIBDs: target antigens & immunofluorescence 4×Jun 2022 · Paper IV · Q5(c) (3 marks) · Dec 2022 · Paper II · Q8(b) (3 marks) · Apr 2023 · Paper II · Q3(a) (5 marks) · Oct 2024 · Paper I · Q6(b) (4 marks)
  2. Bullous pemphigoid & its variants 3×Jun 2020 · Paper IV · Q9(c) (3 marks) · Dec 2021 · Paper II · Q1 (10 marks) · Oct 2023 · Paper IV · Q8(a) (5 marks)
  3. Paraneoplastic pemphigus 2×Oct 2023 · Paper II · Q1(b) (5 marks) · May 2024 · Paper IV · Q9(c) (3 marks)
  4. Subcorneal split disorders: differential diagnosis 1×Dec 2020 · Paper I · Q1(b) (5 marks)
  5. Dermatitis herpetiformis 1×Dec 2022 · Paper II · Q8(c) (3 marks)
  6. Epidermolysis bullosa acquisita 1×May 2024 · Paper I · Q7(b) (3 marks)
  7. Epidermolysis bullosa: pathogenesis & classification 2×Jun 2020 · Paper I · Q1(b) (5 marks) · Jun 2022 · Paper II · Q4(a) (3 marks)
  8. Immunofluorescence mapping in EB 1×Jun 2022 · Paper II · Q4(b) (3 marks)
  9. Kindler syndrome 1×Jun 2022 · Paper II · Q4(c) (4 marks)
  10. Long-term complications of EB 1×Dec 2022 · Paper II · Q8(a) (4 marks)
  11. Epidermolysis bullosa pruriginosa 1×May 2024 · Paper II · Q2(b) (5 marks)
  12. Autoantibodies & ANA in connective tissue diseases 5×Dec 2021 · Paper I · Q3(a) (4 marks) · Dec 2021 · Paper I · Q3(c) (3 marks) · Dec 2022 · Paper II · Q10(b) (3 marks) · Oct 2023 · Paper I · Q7(a) (5 marks) · Oct 2024 · Paper IV · Q5 (10 marks)
  13. Antiphospholipid syndrome / antibody 3×Jun 2020 · Paper IV · Q5(a) (5 marks) · Jun 2021 · Paper II · Q7(a) (5 marks) · Dec 2021 · Paper I · Q3(b) (3 marks)
  14. Dermatomyositis (incl. amyopathic DM) 3×Dec 2020 · Paper II · Q2(a) (4 marks) · Dec 2020 · Paper II · Q2(b) (6 marks) · Dec 2022 · Paper II · Q10(a) (3 marks)
  15. Systemic lupus erythematosus: diagnosis, criteria & treatment 2×Jun 2022 · Paper II · Q3 (10 marks) · May 2024 · Paper II · Q10(c) (3 marks)
  16. Calcinosis cutis 2×May 2024 · Paper IV · Q8(a) (3 marks) · Dec 2025 · Paper II · Q10(b) (5 marks)
  17. Raynaud's phenomenon & nailfold capillaroscopy 2×May 2024 · Paper IV · Q8(b) (3 marks) · Oct 2024 · Paper I · Q7(a) (6 marks)
  18. Systemic sclerosis: diagnosis, investigations, mRSS & management 3×Jun 2022 · Paper II · Q10(b) (4 marks) · Dec 2022 · Paper II · Q9(a) (2 marks) · Apr 2023 · Paper II · Q4 (10 marks)
  19. Eosinophilic fasciitis 1×Dec 2021 · Paper II · Q9(c) (3 marks)
  20. Scleredema 1×Dec 2021 · Paper II · Q9(b) (3 marks)
  21. Scleromyxedema 1×Jun 2022 · Paper II · Q6(c) (4 marks)
  22. Histopathology of scleroderma & scleromyxedema 1×Oct 2023 · Paper II · Q1(a) (5 marks)
Part 10 · Vasculitis, Neutrophilic, Granulomatous and Vascular Disorders24 questions
  1. ANCA-associated vasculitis (incl. polyangiitis) 3×Jun 2021 · Paper IV · Q6 (10 marks) · Dec 2021 · Paper II · Q7(c) (3 marks) · Oct 2023 · Paper IV · Q5 (10 marks)
  2. Classification of vasculitis (Chapel Hill) & approach 3×Dec 2020 · Paper II · Q5(a) (5 marks) · Oct 2024 · Paper II · Q1(a) (3 marks) · Oct 2024 · Paper II · Q1(b) (7 marks)
  3. IgA vasculitis (Henoch Sch nlein purpura) 2×Dec 2021 · Paper II · Q7(b) (4 marks) · May 2024 · Paper II · Q4(a) (4 marks)
  4. Kawasaki disease 1×Dec 2021 · Paper II · Q2(c) (4 marks)
  5. Urticarial vasculitis 1×Dec 2021 · Paper II · Q7(a) (3 marks)
  6. Pigmented purpuric dermatosis (lichen aureus) 1×Jun 2025 · Paper II · Q10(c) (3 marks)
  7. Vasculitis vs vasculopathy; livedoid vasculopathy 2×Jun 2025 · Paper II · Q10(a) (3 marks) · Jun 2025 · Paper II · Q10(b) (4 marks)
  8. Autoinflammatory disorders of skin 3×Dec 2021 · Paper II · Q2(a) (3 marks) · May 2024 · Paper II · Q6(a) (5 marks) · May 2024 · Paper II · Q6(b) (3 marks)
  9. Schnitzler syndrome 1×Dec 2021 · Paper II · Q2(b) (3 marks)
  10. Sweet syndrome & pyoderma gangrenosum: variants & associations 1×Jun 2025 · Paper II · Q8 (10 marks)
  11. Beh et's disease: mucocutaneous manifestations 1×Dec 2025 · Paper II · Q4 (10 marks)
  12. Neutrophilic eccrine hidradenitis 1×Dec 2025 · Paper II · Q5(b) (5 marks)
  13. SAPHO syndrome 1×Dec 2025 · Paper II · Q5(a) (5 marks)
  14. Palisading granulomas 3×Dec 2020 · Paper I · Q4(b) (4 marks) · Dec 2020 · Paper II · Q1(a) (4 marks) · Dec 2025 · Paper I · Q6 (10 marks)
  15. Orofacial granulomatosis 2×Oct 2023 · Paper II · Q6(a) (5 marks) · Dec 2025 · Paper II · Q7 (10 marks)
  16. Sarcoidosis 2×Oct 2023 · Paper II · Q4(a) (5 marks) · May 2024 · Paper II · Q10(a) (3 marks)
  17. Granuloma annulare 1×Dec 2020 · Paper II · Q1(b) (6 marks)
  18. Histopathology of non-infectious granulomas 1×Apr 2023 · Paper I · Q10(a) (4 marks)
  19. Lipodermatosclerosis 2×Jun 2022 · Paper II · Q6(b) (3 marks) · Oct 2024 · Paper II · Q9(b) (5 marks)
  20. Lupus panniculitis (lupus profundus) 2×Oct 2023 · Paper II · Q7(b) (5 marks) · Dec 2025 · Paper II · Q9(b) (5 marks)
  21. Panniculitis: classification 1×Oct 2024 · Paper II · Q9(a) (5 marks)
  22. Chronic leg ulcer: investigation 1×Dec 2020 · Paper II · Q5(b) (5 marks)
  23. Chronic venous disease: evaluation, CEAP, sclerotherapy & compression 1×Dec 2022 · Paper IV · Q3 (10 marks)
  24. Anatomy & physiology of lower-limb venous system 1×Apr 2023 · Paper I · Q2(a) (5 marks)
Part 11 · Pigmentary, Hair, Nail and Adnexal Disorders32 questions
  1. Vitiligo surgery (NCES, NCMT, acrofacial) 4×Dec 2021 · Paper IV · Q6(b) (3 marks) · Jun 2022 · Paper IV · Q4(a) (4 marks) · Dec 2022 · Paper IV · Q1(a) (5 marks) · May 2024 · Paper II · Q7(a) (3 marks)
  2. Vitiligo: psychosocial impact & counselling 3×Dec 2020 · Paper II · Q10(a) (6 marks) · Dec 2020 · Paper II · Q10(b) (4 marks) · Dec 2021 · Paper IV · Q8(c) (3 marks)
  3. Phototherapy in vitiligo (NB-UVB, home phototherapy) 2×Jun 2022 · Paper II · Q7(a) (3 marks) · Apr 2023 · Paper II · Q9(a) (6 marks)
  4. Vitiligo: newer & topical biologic treatments 1×Jun 2022 · Paper IV · Q2(c) (3 marks)
  5. Vitiligo: aetiopathogenesis 1×Dec 2022 · Paper II · Q9(d) (2 marks)
  6. Hypopigmented lesions in infancy: differential diagnosis 1×May 2024 · Paper I · Q8(b) (4 marks)
  7. Melasma: aetiology, management & recent advances 5×Jun 2020 · Paper IV · Q5(b) (5 marks) · Dec 2020 · Paper II · Q3(b) (6 marks) · Jun 2022 · Paper IV · Q8(b) (3 marks) · Dec 2022 · Paper II · Q9(c) (2 marks) · May 2024 · Paper II · Q7(b) (3 marks)
  8. Facial hyperpigmentation: differential diagnosis 1×Dec 2020 · Paper II · Q3(a) (4 marks)
  9. Frictional melanosis & maturational hyperpigmentation 2×Jun 2025 · Paper II · Q2(b) (2 marks) · Jun 2025 · Paper II · Q2(c) (2 marks)
  10. Skin lightening agents 1×Dec 2025 · Paper IV · Q8(a) (5 marks)
  11. Primary cicatricial alopecias: classification, LPP & FFA 3×Jun 2020 · Paper II · Q9(a) (5 marks) · Jun 2020 · Paper II · Q9(b) (5 marks) · Dec 2025 · Paper II · Q9(a) (5 marks)
  12. Hair evaluation: hair pull test, trichogram 2×Dec 2020 · Paper I · Q10(c) (3 marks) · Jun 2022 · Paper IV · Q3(c) (4 marks)
  13. Androgenetic alopecia & female pattern hair loss 2×Dec 2022 · Paper IV · Q5(b) (4 marks) · Apr 2023 · Paper IV · Q6(b) (6 marks)
  14. Scalp biopsy in alopecias 2×Apr 2023 · Paper I · Q1(b) (5 marks) · Oct 2024 · Paper I · Q4(b) (5 marks)
  15. Alopecia areata 1×Jun 2020 · Paper II · Q3(c) (2 marks)
  16. Telogen effluvium (post-COVID) & diffuse hair loss 1×Dec 2021 · Paper II · Q6 (10 marks)
  17. Hair shaft disorders: enumeration 1×May 2024 · Paper I · Q9(c) (4 marks)
  18. Non-scarring alopecias: classification 1×May 2024 · Paper I · Q9(a) (2 marks)
  19. Nail psoriasis & nail lichen planus 2×Jun 2021 · Paper I · Q5(a) (6 marks) · Jun 2025 · Paper I · Q4(c) (4 marks)
  20. Ingrown toenail (onychocryptosis): surgical management 2×Jun 2022 · Paper IV · Q9(c) (5 marks) · Oct 2024 · Paper IV · Q7(a) (5 marks)
  21. Nail signs: matrix changes & Beau's lines 2×Dec 2021 · Paper I · Q2(b) (4 marks) · Dec 2021 · Paper I · Q2(c) (3 marks)
  22. Injection therapy in nail disorders 1×Apr 2023 · Paper II · Q5(b) (6 marks)
  23. Onycholysis 1×Apr 2023 · Paper II · Q5(a) (4 marks)
  24. Drug-induced nail changes 1×Dec 2025 · Paper IV · Q9(b) (5 marks)
  25. Hormonal acne, hormonal therapy & PCOS 3×Jun 2020 · Paper IV · Q2(b) (5 marks) · Dec 2022 · Paper II · Q7(b) (5 marks) · Jun 2025 · Paper II · Q4(b) (5 marks)
  26. Acne-related syndromes 1×Jun 2020 · Paper IV · Q2(a) (5 marks)
  27. Newer topical therapies for acne 1×Jun 2021 · Paper IV · Q1(c) (4 marks)
  28. Rosacea: pathogenesis & histopathology 3×Dec 2020 · Paper I · Q4(c) (2 marks) · Jun 2021 · Paper II · Q5(a) (5 marks) · May 2024 · Paper II · Q2(a) (5 marks)
  29. Rosacea: subtypes & treatment 3×Jun 2021 · Paper II · Q5(b) (5 marks) · Oct 2023 · Paper II · Q9 (10 marks) · Dec 2025 · Paper II · Q10(a) (5 marks)
  30. Hidradenitis suppurativa: pathogenesis, staging, complications & management 5×Dec 2020 · Paper IV · Q1(a) (5 marks) · Jun 2022 · Paper II · Q5 (10 marks) · Dec 2022 · Paper IV · Q2 (10 marks) · Apr 2023 · Paper II · Q7 (10 marks) · Jun 2025 · Paper II · Q6 (10 marks)
  31. Follicular occlusion tetrad 1×May 2024 · Paper II · Q6(c) (2 marks)
  32. Hirsutism & hyperandrogenism: causes, evaluation & treatment 5×Jun 2021 · Paper II · Q9(a) (3 marks) · Jun 2021 · Paper II · Q9(b) (7 marks) · Dec 2022 · Paper II · Q7(a) (5 marks) · Apr 2023 · Paper II · Q2 (10 marks) · Dec 2025 · Paper II · Q6(a) (6 marks)
Part 12 · Infections and Infestations30 questions
  1. Staphylococcal infections, SSSS & MRSA 3×Jun 2021 · Paper IV · Q5(b) (5 marks) · Dec 2021 · Paper I · Q5(b) (3 marks) · Dec 2022 · Paper IV · Q4(b) (5 marks)
  2. Bacillary angiomatosis 1×Jun 2022 · Paper II · Q10(c) (3 marks)
  3. Lyme disease & erythema chronicum migrans 2×Oct 2024 · Paper II · Q2(a) (2 marks) · Oct 2024 · Paper II · Q2(b) (3 marks)
  4. Gram-negative folliculitis 1×Dec 2025 · Paper II · Q6(b) (4 marks)
  5. Tuberculids (incl. papulonecrotic tuberculid) 4×Dec 2021 · Paper II · Q3(a) (4 marks) · Oct 2023 · Paper II · Q8(b) (5 marks) · May 2024 · Paper II · Q1(a) (6 marks) · Dec 2025 · Paper II · Q8(b) (5 marks)
  6. Atypical mycobacteria (swimming pool granuloma, NTM) 2×Jun 2021 · Paper IV · Q5(a) (5 marks) · Oct 2023 · Paper II · Q10(a) (6 marks)
  7. MDR / XDR tuberculosis 2×Dec 2021 · Paper II · Q3(b) (3 marks) · Jun 2025 · Paper II · Q5(a) (4 marks)
  8. Cutaneous tuberculosis: M. tuberculosis & pathogenesis of the spectrum 2×Oct 2024 · Paper I · Q9(a) (4 marks) · Oct 2024 · Paper I · Q9(b) (6 marks)
  9. Mycetoma: classification, histopathology, diagnosis & management 3×Dec 2021 · Paper II · Q4(c) (4 marks) · Oct 2023 · Paper II · Q2(a) (5 marks) · May 2024 · Paper II · Q8 (10 marks)
  10. Recalcitrant dermatophytosis in India (incl. T. indotineae) 3×Dec 2021 · Paper II · Q4(a) (3 marks) · Jun 2022 · Paper II · Q9(b) (5 marks) · Dec 2025 · Paper IV · Q7(b) (5 marks)
  11. Antifungal drug resistance: mechanisms & testing 3×Dec 2022 · Paper I · Q8(b) (5 marks) · Apr 2023 · Paper I · Q7(b) (5 marks) · Oct 2024 · Paper I · Q6(a) (6 marks)
  12. Antifungal drugs (topical & systemic azoles, naftifine) 3×Dec 2022 · Paper IV · Q8(c) (4 marks) · Apr 2023 · Paper II · Q8(b) (5 marks) · Oct 2023 · Paper IV · Q2(b) (3 marks)
  13. Tinea capitis in children: treatment 1×Dec 2021 · Paper II · Q4(b) (3 marks)
  14. MALDI-TOF MS in dermatophytes 1×Dec 2022 · Paper I · Q3(c) (2 marks)
  15. Sporotrichoid lesions: differential diagnosis 1×Dec 2022 · Paper II · Q5(a) (5 marks)
  16. Onychomycosis & non-dermatophyte moulds 1×Apr 2023 · Paper I · Q6(b) (5 marks)
  17. Warts: periungual & recalcitrant warts 3×Jun 2020 · Paper II · Q3(a) (4 marks) · Apr 2023 · Paper I · Q2(b) (5 marks) · May 2024 · Paper IV · Q10(a) (3 marks)
  18. Chikungunya 2×Jun 2020 · Paper IV · Q3(b) (3 marks) · Apr 2023 · Paper IV · Q8(b) (5 marks)
  19. Molluscum contagiosum 2×Jun 2020 · Paper II · Q3(b) (4 marks) · Oct 2024 · Paper III · Q5(a) (4 marks)
  20. Herpes zoster: post-herpetic neuralgia & zoster vaccine 2×Dec 2020 · Paper IV · Q4(a) (5 marks) · Oct 2023 · Paper IV · Q2(a) (4 marks)
  21. Poxvirus infections (incl. mpox) 2×Apr 2023 · Paper I · Q6(a) (5 marks) · May 2024 · Paper II · Q1(b) (4 marks)
  22. Dengue 1×Jun 2020 · Paper IV · Q3(c) (3 marks)
  23. Eczema herpeticum 1×Jun 2020 · Paper II · Q7 (10 marks)
  24. Cutaneous manifestations of hepatitis B, hepatitis C & EBV 1×Dec 2022 · Paper II · Q4 (10 marks)
  25. Cutaneous leishmaniasis: classification, diagnosis & treatment 2×Jun 2020 · Paper II · Q1 (10 marks) · Jun 2025 · Paper II · Q5(b) (6 marks)
  26. Scabies (incl. nodular scabies) 2×Jun 2020 · Paper IV · Q9(b) (3 marks) · Jun 2022 · Paper II · Q1 (10 marks)
  27. Pediculosis: head lice & phthiriasis pubis 2×Dec 2020 · Paper III · Q2(a) (5 marks) · Apr 2023 · Paper II · Q10(c) (3 marks)
  28. Post kala-azar dermal leishmaniasis (PKDL) 2×Dec 2021 · Paper II · Q3(c) (3 marks) · Oct 2023 · Paper II · Q2(b) (5 marks)
  29. Cutaneous larva migrans & myiasis 2×Apr 2023 · Paper II · Q10(a) (4 marks) · Apr 2023 · Paper II · Q10(b) (3 marks)
  30. Demodex & skin 1×Dec 2025 · Paper IV · Q1(a) (5 marks)
Part 13 · Genetic, Metabolic and Nutritional Disorders; Skin in Systemic Disease26 questions
  1. Ichthyoses: classification, diagnostic clues & syndromic ichthyosis 4×Jun 2022 · Paper IV · Q7(b) (5 marks) · Dec 2022 · Paper II · Q3(a) (5 marks) · Dec 2022 · Paper II · Q3(b) (2 marks) · Oct 2023 · Paper II · Q4(b) (5 marks)
  2. Collodion baby 2×Dec 2021 · Paper II · Q5(c) (3 marks) · Dec 2022 · Paper II · Q3(c) (3 marks)
  3. Xeroderma pigmentosum 2×Dec 2021 · Paper I · Q10(b) (4 marks) · May 2024 · Paper II · Q9(b) (5 marks)
  4. Genodermatoses with photosensitivity 1×Dec 2020 · Paper I · Q9(b) (6 marks)
  5. Silvery hair syndromes 1×Dec 2021 · Paper I · Q4(c) (3 marks)
  6. Tuberous sclerosis complex 1×Apr 2023 · Paper II · Q6(b) (5 marks)
  7. Ehlers Danlos syndrome 1×Oct 2024 · Paper II · Q7 (10 marks)
  8. Premature ageing syndromes 1×Jun 2025 · Paper I · Q6(b) (5 marks)
  9. Heme biosynthesis pathway & classification of porphyrias 4×Jun 2021 · Paper II · Q6(a) (3 marks) · Dec 2022 · Paper I · Q9(a) (3 marks) · May 2024 · Paper II · Q3(b) (6 marks) · Oct 2024 · Paper I · Q3(a) (3 marks)
  10. Cutaneous porphyrias (incl. PCT): clinical & histopathology 3×Dec 2022 · Paper I · Q9(b) (3 marks) · Oct 2024 · Paper I · Q3(b) (3 marks) · Oct 2024 · Paper I · Q3(c) (4 marks)
  11. Erythropoietic protoporphyria 1×Jun 2021 · Paper II · Q6(b) (7 marks)
  12. Cutaneous amyloidosis 5×Jun 2020 · Paper IV · Q9(a) (4 marks) · Dec 2020 · Paper II · Q7(a) (5 marks) · Dec 2021 · Paper IV · Q2(c) (3 marks) · Jun 2022 · Paper II · Q6(a) (3 marks) · Dec 2022 · Paper II · Q10(c) (4 marks)
  13. Xanthomas & xanthelasma palpebrarum 3×Dec 2020 · Paper II · Q7(b) (5 marks) · Dec 2021 · Paper IV · Q1(b) (4 marks) · Dec 2021 · Paper IV · Q1(c) (2 marks)
  14. Alkaptonuria 1×Dec 2021 · Paper IV · Q2(b) (3 marks)
  15. Zinc deficiency 2×Jun 2020 · Paper IV · Q4(b) (5 marks) · Dec 2022 · Paper I · Q10(c) (3 marks)
  16. Vitamin deficiencies & skin (water-soluble, vitamin A) 2×Jun 2021 · Paper II · Q8(a) (4 marks) · Dec 2022 · Paper I · Q10(b) (3 marks)
  17. Pellagra 1×Jun 2021 · Paper II · Q8(b) (6 marks)
  18. Metabolic syndrome, obesity & acanthosis nigricans 4×Dec 2021 · Paper IV · Q1(a) (4 marks) · Dec 2022 · Paper II · Q9(e) (2 marks) · Oct 2023 · Paper IV · Q8(b) (5 marks) · Dec 2025 · Paper IV · Q5(a) (5 marks)
  19. Paraneoplastic dermatoses & cutaneous markers of internal malignancy 3×Jun 2021 · Paper IV · Q4 (10 marks) · May 2024 · Paper IV · Q8(c) (4 marks) · Oct 2024 · Paper IV · Q1(a) (6 marks)
  20. Hypereosinophilic syndrome 1×Jun 2020 · Paper II · Q8(b) (5 marks)
  21. Cutaneous manifestations of endocrine (adrenal) disorders 1×Jun 2021 · Paper IV · Q7 (10 marks)
  22. Graft-versus-host disease 1×Dec 2021 · Paper II · Q9(a) (4 marks)
  23. Kikuchi Fujimoto disease 1×Oct 2023 · Paper II · Q10(b) (4 marks)
  24. Sacroiliitis in dermatology 1×Oct 2023 · Paper IV · Q3 (10 marks)
  25. Cutaneous manifestations of cardiac disease 1×Oct 2024 · Paper IV · Q1(b) (4 marks)
  26. Rheumatoid arthritis & accelerated rheumatoid nodulosis 1×Oct 2024 · Paper II · Q8 (10 marks)
Part 14 · Paediatric, Pregnancy, Erythroderma and Photodermatoses8 questions
  1. Neonatal vesiculopustular & transient neonatal dermatoses 3×Dec 2021 · Paper II · Q5(b) (4 marks) · Dec 2022 · Paper II · Q5(b) (5 marks) · Jun 2025 · Paper II · Q1(b) (5 marks)
  2. Physiological skin changes in the newborn 1×Oct 2023 · Paper II · Q8(a) (5 marks)
  3. Specific dermatoses of pregnancy 4×Jun 2020 · Paper IV · Q4(a) (5 marks) · Dec 2020 · Paper II · Q8 (10 marks) · Jun 2021 · Paper II · Q4(a) (3 marks) · May 2024 · Paper II · Q7(c) (4 marks)
  4. Impetigo herpetiformis (pustular psoriasis of pregnancy) 2×Jun 2020 · Paper II · Q4(a) (5 marks) · Jun 2022 · Paper IV · Q7(a) (5 marks)
  5. Pemphigoid gestationis 2×Jun 2020 · Paper II · Q4(b) (5 marks) · Jun 2021 · Paper II · Q4(b) (7 marks)
  6. Physiological skin changes in pregnancy 1×Dec 2022 · Paper I · Q9(c) (4 marks)
  7. Erythroderma in children 2×Dec 2020 · Paper II · Q6(a) (4 marks) · Apr 2023 · Paper IV · Q5 (10 marks)
  8. Idiopathic & photoaggravated photodermatoses 2×Dec 2022 · Paper II · Q6(b) (3 marks) · May 2024 · Paper II · Q10(b) (4 marks)
Part 15 · Cutaneous Oncology18 questions
  1. Basal cell carcinoma: pathogenesis, hedgehog pathway, topical agents & vismodegib 2×Dec 2021 · Paper IV · Q3 (10 marks) · Oct 2023 · Paper IV · Q9(b) (5 marks)
  2. Non-melanoma skin cancer: risk factors, chemicals & genetic syndromes 2×Dec 2022 · Paper II · Q1 (10 marks) · Oct 2024 · Paper IV · Q4(a) (3 marks)
  3. Bowen's disease & actinic keratosis 2×May 2024 · Paper I · Q6(b) (4 marks) · Oct 2024 · Paper II · Q5(c) (5 marks)
  4. Extramammary Paget disease 1×Apr 2023 · Paper II · Q9(b) (4 marks)
  5. Seborrhoeic keratosis: histopathology 1×Apr 2023 · Paper I · Q5(a) (5 marks)
  6. Painful skin tumours 1×Jun 2022 · Paper IV · Q9(b) (3 marks)
  7. Cutaneous metastases 1×Apr 2023 · Paper IV · Q1(a) (5 marks)
  8. Targeted therapy & immunotherapy in skin cancers 1×Oct 2024 · Paper IV · Q4(b) (7 marks)
  9. CTCL: WHO-EORTC classification & variants 2×Jun 2020 · Paper II · Q10(c) (5 marks) · Jun 2022 · Paper IV · Q5(a) (4 marks)
  10. Pseudolymphoma 2×Jun 2020 · Paper II · Q10(a) (2 marks) · Jun 2020 · Paper II · Q10(b) (3 marks)
  11. CTCL: immunohistochemistry 1×Jun 2022 · Paper IV · Q5(b) (3 marks)
  12. Mycosis fungoides (incl. hypopigmented MF) 1×Apr 2023 · Paper IV · Q1(b) (5 marks)
  13. Langerhans cell histiocytosis & classification of histiocytoses 2×Dec 2021 · Paper IV · Q2(a) (4 marks) · May 2024 · Paper II · Q3(a) (4 marks)
  14. Immunohistochemical markers of histiocytoses 1×Apr 2023 · Paper I · Q5(b) (5 marks)
  15. Infantile haemangioma: management 4×Dec 2020 · Paper IV · Q1(b) (5 marks) · Jun 2022 · Paper IV · Q6(a) (3 marks) · May 2024 · Paper II · Q9(a) (5 marks) · Oct 2024 · Paper IV · Q8(b) (4 marks)
  16. Angiolymphoid hyperplasia with eosinophilia 1×Jun 2020 · Paper II · Q8(a) (5 marks)
  17. Pyogenic granuloma 1×Jun 2021 · Paper II · Q7(b) (5 marks)
  18. Vascular malformations: classification 1×Oct 2024 · Paper IV · Q8(a) (6 marks)
Part 16 · Psychodermatology, Environmental and Miscellaneous Dermatoses13 questions
  1. Trichotillomania 3×Dec 2021 · Paper IV · Q8(a) (4 marks) · Jun 2022 · Paper II · Q7(b) (3 marks) · Oct 2024 · Paper II · Q4(b) (6 marks)
  2. Body dysmorphic disorder 2×Dec 2021 · Paper IV · Q8(b) (3 marks) · Jun 2022 · Paper II · Q7(c) (4 marks)
  3. Classification of psychodermatological disorders 1×Oct 2024 · Paper II · Q4(a) (4 marks)
  4. Delusional parasitosis 1×Dec 2025 · Paper II · Q8(a) (5 marks)
  5. Air pollution & skin 4×Jun 2020 · Paper IV · Q7(a) (4 marks) · Oct 2023 · Paper IV · Q9(a) (5 marks) · May 2024 · Paper I · Q10(c) (3 marks) · Dec 2025 · Paper IV · Q4 (10 marks)
  6. Chronic arsenic toxicity 2×Apr 2023 · Paper II · Q6(a) (5 marks) · Oct 2024 · Paper II · Q10 (10 marks)
  7. Dermatoses at high altitude & in desert areas 2×Jun 2020 · Paper IV · Q7(b) (3 marks) · Jun 2020 · Paper IV · Q7(c) (3 marks)
  8. IV drug abuse & nicotine: effects on skin 2×Jun 2025 · Paper II · Q7(a) (5 marks) · Jun 2025 · Paper II · Q7(b) (5 marks)
  9. Perforating disorders (incl. reactive perforating collagenosis) 2×Dec 2021 · Paper I · Q7(a) (6 marks) · May 2024 · Paper II · Q5(a) (5 marks)
  10. Diet & dermatology (incl. acne) 2×Jun 2022 · Paper IV · Q8(c) (3 marks) · Jun 2025 · Paper II · Q4(a) (5 marks)
  11. Annular & figurate erythemas 2×May 2024 · Paper II · Q4(c) (4 marks) · Oct 2024 · Paper II · Q2(c) (5 marks)
  12. Porokeratosis 1×Jun 2020 · Paper II · Q5 (10 marks)
  13. Gender & dermatology 1×Jun 2025 · Paper II · Q1(a) (5 marks)

Volume 3 — Venereology & HIV, Leprosy, Dermatosurgery & Aesthetics, Recent Advances

Part 17 · Genital Anatomy and Sexually Transmitted Infections35 questions
  1. Female genitalia: labelled diagram & Bartholin glands 3×Dec 2021 · Paper I · Q6(a) (4 marks) · Dec 2021 · Paper I · Q6(b) (3 marks) · Jun 2022 · Paper III · Q8(c) (3 marks)
  2. Male genital tract: labelled diagram 1×Dec 2020 · Paper III · Q3 (10 marks)
  3. Congenital syphilis: clinical features, diagnosis & management 7×Jun 2020 · Paper III · Q5(b) (5 marks) · Dec 2020 · Paper III · Q4(a) (5 marks) · Jun 2022 · Paper III · Q3(b) (4 marks) · Dec 2022 · Paper III · Q2(b) (5 marks) · Apr 2023 · Paper III · Q8(a) (4 marks) · Oct 2024 · Paper III · Q2(b) (7 marks) · Jun 2025 · Paper III · Q9(b) (4 marks)
  4. Syphilis in pregnancy 2×Dec 2020 · Paper III · Q4(b) (5 marks) · Jun 2022 · Paper III · Q3(a) (6 marks)
  5. Chancre redux, serofast state & reinfection 2×Jun 2021 · Paper III · Q5(b) (5 marks) · Dec 2025 · Paper III · Q4(b) (3 marks)
  6. Jarisch Herxheimer reaction 2×Jun 2021 · Paper III · Q5(a) (5 marks) · Jun 2025 · Paper III · Q9(c) (3 marks)
  7. Biological false-positive VDRL 2×Dec 2021 · Paper III · Q4(b) (3 marks) · Oct 2023 · Paper III · Q7(b) (5 marks)
  8. Prozone phenomenon 2×Dec 2021 · Paper III · Q4(c) (3 marks) · Apr 2023 · Paper III · Q8(b) (3 marks)
  9. Serological tests, reverse algorithm & monitoring of treatment 2×Jun 2022 · Paper III · Q10(b) (3 marks) · Jun 2025 · Paper III · Q9(a) (3 marks)
  10. Secondary syphilis & classification of syphilis 2×Apr 2023 · Paper III · Q10(b) (5 marks) · Oct 2024 · Paper III · Q2(a) (3 marks)
  11. Animal models of syphilis 1×Jun 2022 · Paper III · Q5(b) (5 marks)
  12. Complications of gonorrhoea 5×Jun 2020 · Paper III · Q4(c) (4 marks) · Jun 2021 · Paper III · Q3(a) (5 marks) · Oct 2023 · Paper III · Q2(a) (5 marks) · May 2024 · Paper III · Q2(c) (3 marks) · Dec 2025 · Paper III · Q1(b) (5 marks)
  13. PPNG & antimicrobial resistance in gonorrhoea 5×Jun 2020 · Paper III · Q4(b) (4 marks) · Dec 2021 · Paper III · Q2(c) (3 marks) · Jun 2022 · Paper III · Q4(b) (4 marks) · Oct 2023 · Paper III · Q2(b) (5 marks) · May 2024 · Paper III · Q2(b) (3 marks)
  14. Neisseria gonorrhoeae: structure & gonococcal urethritis 2×Jun 2020 · Paper III · Q4(a) (2 marks) · May 2024 · Paper III · Q2(a) (4 marks)
  15. Mycoplasma genitalium & genital mycoplasmas 3×Jun 2022 · Paper III · Q4(a) (3 marks) · Dec 2022 · Paper III · Q2(a) (5 marks) · Jun 2025 · Paper III · Q8(a) (5 marks)
  16. Urethral discharge in men: approach & investigations 2×Dec 2021 · Paper III · Q3(a) (4 marks) · Apr 2023 · Paper III · Q9(a) (5 marks)
  17. Non-gonococcal urethritis: aetiology & management 2×Apr 2023 · Paper III · Q9(b) (5 marks) · Oct 2024 · Paper III · Q4(a) (6 marks)
  18. Herpes in pregnancy & neonatal herpes 4×Dec 2021 · Paper III · Q1(c) (2 marks) · Apr 2023 · Paper III · Q5(a) (4 marks) · Dec 2025 · Paper III · Q5(a) (5 marks) · Dec 2025 · Paper III · Q5(b) (5 marks)
  19. Acyclovir-resistant / persistent genital herpes 3×Jun 2022 · Paper III · Q4(c) (3 marks) · Dec 2022 · Paper III · Q4(a) (5 marks) · May 2024 · Paper III · Q3(b) (3 marks)
  20. Genital herpes: diagnosis (incl. type-specific serology) 2×Dec 2021 · Paper III · Q1(b) (4 marks) · May 2024 · Paper III · Q3(c) (4 marks)
  21. Recurrent genital herpes: suppressive therapy 1×May 2024 · Paper III · Q3(a) (3 marks)
  22. Anogenital warts: treatment (incl. persistent & paediatric) 3×Jun 2021 · Paper III · Q2(b) (5 marks) · May 2024 · Paper III · Q9(b) (5 marks) · Jun 2025 · Paper III · Q7(a) (5 marks)
  23. HPV vaccines (incl. nonavalent) 3×Jun 2021 · Paper III · Q2(a) (5 marks) · Dec 2021 · Paper III · Q5(c) (3 marks) · Jun 2022 · Paper III · Q7(a) (3 marks)
  24. HPV genotypes, clinical manifestations & HPV-related cancers 3×Dec 2021 · Paper III · Q5(b) (3 marks) · Jun 2022 · Paper III · Q6(a) (3 marks) · Dec 2022 · Paper III · Q10(a) (5 marks)
  25. Bowenoid papulosis 2×May 2024 · Paper III · Q10(b) (3 marks) · Dec 2025 · Paper III · Q4(a) (4 marks)
  26. Buschke L wenstein tumour 1×Apr 2023 · Paper III · Q2(a) (4 marks)
  27. Inguinal bubo: approach, syndromic management & chancroid vs LGV 3×Jun 2020 · Paper III · Q1(a) (5 marks) · Oct 2023 · Paper III · Q4(b) (5 marks) · Oct 2024 · Paper III · Q5(b) (6 marks)
  28. Lymphogranuloma venereum 3×Jun 2020 · Paper III · Q2 (10 marks) · Jun 2022 · Paper III · Q7(c) (4 marks) · Apr 2023 · Paper III · Q8(c) (3 marks)
  29. Genital ulcer disease: differential diagnosis & approach 1×Dec 2021 · Paper III · Q1(a) (4 marks)
  30. Bacterial vaginosis: diagnosis (Amsel, Nugent, clue cells) & complications 6×Jun 2021 · Paper III · Q4 (10 marks) · Jun 2022 · Paper III · Q9(b) (3 marks) · Dec 2022 · Paper III · Q8(a) (3 marks) · Dec 2022 · Paper III · Q8(b) (3 marks) · Jun 2025 · Paper III · Q3(a) (5 marks) · Dec 2025 · Paper III · Q4(c) (3 marks)
  31. Vaginal discharge: approach (incl. pregnancy & prepubertal girls) 3×Dec 2021 · Paper III · Q2(a) (4 marks) · Oct 2024 · Paper III · Q1(b) (7 marks) · Dec 2025 · Paper IV · Q6(a) (5 marks)
  32. Normal flora / microbiome of female genital tract 2×Jun 2022 · Paper I · Q9(b) (4 marks) · Oct 2024 · Paper III · Q1(a) (3 marks)
  33. Vulvovaginal candidiasis (incl. complicated VVC) 2×Jun 2022 · Paper III · Q9(c) (4 marks) · Oct 2023 · Paper III · Q8(a) (5 marks)
  34. Trichomoniasis: laboratory diagnosis 1×Jun 2022 · Paper III · Q9(a) (3 marks)
  35. Cytolytic vaginitis 1×Dec 2025 · Paper IV · Q3(c) (4 marks)
Part 18 · Syndromic Management, HIV and STI Programmes34 questions
  1. Syndromic management of vaginal discharge & cervicitis 3×Dec 2021 · Paper III · Q2(b) (3 marks) · Dec 2022 · Paper III · Q4(b) (5 marks) · Jun 2025 · Paper III · Q3(b) (5 marks)
  2. Syndromic management of genital ulcer disease 2×Jun 2020 · Paper III · Q1(b) (5 marks) · May 2024 · Paper III · Q4(a) (4 marks)
  3. Syndromic management of lower abdominal pain (PID) 3×Dec 2020 · Paper III · Q1(a) (6 marks) · Dec 2020 · Paper III · Q1(b) (4 marks) · May 2024 · Paper III · Q4(c) (3 marks)
  4. Syndromic management of urethral discharge 1×May 2024 · Paper III · Q4(b) (3 marks)
  5. Syndromic case management: principles, advantages & limitations 1×Dec 2025 · Paper III · Q3 (10 marks)
  6. Antiretroviral drugs: classification, targets & newer drugs 3×Jun 2020 · Paper III · Q3(a) (6 marks) · Dec 2022 · Paper III · Q6(b) (5 marks) · Jun 2025 · Paper IV · Q9(a) (4 marks)
  7. HIV & other STIs: impact on GUD, herpes, chancroid, viral STIs 4×Dec 2021 · Paper III · Q5(a) (4 marks) · Apr 2023 · Paper III · Q2(b) (6 marks) · Oct 2023 · Paper III · Q5(a) (5 marks) · Oct 2023 · Paper III · Q5(b) (5 marks)
  8. Integrase inhibitors 2×Jun 2020 · Paper III · Q3(b) (4 marks) · Dec 2020 · Paper III · Q5(a) (5 marks)
  9. PrEP & PEP for HIV 3×Dec 2020 · Paper III · Q5(b) (5 marks) · Jun 2025 · Paper IV · Q2(b) (3 marks) · Jun 2025 · Paper IV · Q2(c) (4 marks)
  10. Structure & life cycle of HIV / retrovirus 2×Jun 2021 · Paper III · Q1(a) (4 marks) · Dec 2022 · Paper III · Q6(a) (5 marks)
  11. Cutaneous manifestations & opportunistic infections in HIV 2×Jun 2022 · Paper III · Q7(b) (3 marks) · Apr 2023 · Paper III · Q4(a) (5 marks)
  12. Adverse effects of ART & their cutaneous manifestations 2×Dec 2022 · Paper III · Q10(b) (5 marks) · Apr 2023 · Paper III · Q4(b) (5 marks)
  13. ART regimens (adult & paediatric) & monitoring 2×Apr 2023 · Paper III · Q5(b) (6 marks) · Oct 2024 · Paper III · Q4(b) (4 marks)
  14. Immune reconstitution inflammatory syndrome (IRIS) 1×Jun 2021 · Paper III · Q1(b) (6 marks)
  15. Kaposi sarcoma 1×Jun 2022 · Paper III · Q10(a) (3 marks)
  16. HIV testing: pre- & post-test counselling 1×Apr 2023 · Paper III · Q10(a) (5 marks)
  17. Persistent generalized lymphadenopathy 1×Oct 2024 · Paper III · Q3(a) (5 marks)
  18. Child sexual abuse, POCSO Act & STI evaluation in children 5×Jun 2022 · Paper III · Q8(a) (3 marks) · Jun 2022 · Paper III · Q8(b) (4 marks) · Oct 2023 · Paper III · Q4(a) (5 marks) · Jun 2025 · Paper III · Q10(b) (6 marks) · Dec 2025 · Paper III · Q1(a) (5 marks)
  19. Anorectal STIs: proctitis, gay bowel syndrome, anorectal discharge 4×Dec 2021 · Paper III · Q3(b) (3 marks) · Dec 2021 · Paper III · Q3(c) (3 marks) · Oct 2024 · Paper III · Q3(b) (5 marks) · Dec 2025 · Paper III · Q2 (10 marks)
  20. STIs in men who have sex with men (MSM) 2×Oct 2023 · Paper III · Q3(a) (5 marks) · Dec 2025 · Paper IV · Q8(b) (5 marks)
  21. Arthritis associated with STIs 1×Jun 2021 · Paper III · Q3(b) (5 marks)
  22. Partner management in STIs 1×Jun 2025 · Paper III · Q10(a) (4 marks)
  23. Venereophobia 1×Dec 2025 · Paper III · Q10(b) (5 marks)
  24. Non-venereal genital ulcers & Lipschutz ulcer 3×Dec 2020 · Paper III · Q2(b) (5 marks) · Oct 2023 · Paper III · Q10(b) (5 marks) · Dec 2025 · Paper IV · Q6(b) (5 marks)
  25. Vulvar pruritus & non-venereal vulvar dermatoses 3×Dec 2021 · Paper I · Q6(c) (3 marks) · May 2024 · Paper III · Q8(b) (5 marks) · Jun 2025 · Paper III · Q8(b) (5 marks)
  26. Lichen sclerosus (genital & extragenital) 2×Jun 2022 · Paper III · Q6(c) (4 marks) · Oct 2023 · Paper II · Q5(b) (5 marks)
  27. Plasma cell balanitis 1×Jun 2022 · Paper III · Q6(b) (3 marks)
  28. Genital Crohn's disease 1×May 2024 · Paper III · Q10(c) (4 marks)
  29. Red scrotum 1×May 2024 · Paper III · Q10(a) (3 marks)
  30. Point-of-care tests for STIs 2×Jun 2020 · Paper III · Q5(a) (5 marks) · May 2024 · Paper III · Q9(a) (5 marks)
  31. PCR / NAAT in STIs 2×Dec 2021 · Paper III · Q4(a) (4 marks) · Oct 2023 · Paper III · Q7(a) (5 marks)
  32. National AIDS Control Programme (NACP-V) 1×Dec 2022 · Paper III · Q8(c) (4 marks)
  33. Doxy-PEP 1×Jun 2025 · Paper IV · Q2(a) (3 marks)
  34. EGASP (Enhanced Gonococcal AMR Surveillance) 1×Jun 2025 · Paper IV · Q9(b) (2 marks)
Part 19 · Leprosy: Basic Science, Classification and Diagnosis20 questions
  1. Host factors, HLA & immune response in leprosy 3×Jun 2021 · Paper III · Q6(a) (5 marks) · Oct 2023 · Paper III · Q6(a) (5 marks) · Oct 2024 · Paper III · Q6(a) (5 marks)
  2. Experimental leprosy & animal models 2×Jun 2021 · Paper III · Q10 (10 marks) · Jun 2022 · Paper III · Q5(a) (5 marks)
  3. Lepromin test 1×Jun 2021 · Paper III · Q6(b) (5 marks)
  4. Nodular lesions in leprosy: differential diagnosis 2×Oct 2023 · Paper III · Q10(a) (5 marks) · Dec 2025 · Paper III · Q8(b) (5 marks)
  5. Ridley Jopling classification 1×Jun 2021 · Paper III · Q7(a) (7 marks)
  6. Differentiating points across the leprosy spectrum (sub-polar LL, histoid, BT vs BB) 1×May 2024 · Paper III · Q5 (10 marks)
  7. Atypical presentations of leprosy 4×Jun 2020 · Paper III · Q10(c) (3 marks) · Dec 2020 · Paper III · Q9 (10 marks) · Oct 2023 · Paper III · Q9(b) (5 marks) · Dec 2025 · Paper III · Q6(a) (5 marks)
  8. Childhood leprosy 4×Jun 2020 · Paper III · Q10(a) (3 marks) · Dec 2021 · Paper III · Q7(c) (3 marks) · Oct 2023 · Paper III · Q9(a) (5 marks) · Jun 2025 · Paper III · Q2(b) (5 marks)
  9. Histoid leprosy (clinical, diagnosis, histopathology) 4×Jun 2020 · Paper III · Q8 (10 marks) · Dec 2020 · Paper III · Q7(b) (5 marks) · Dec 2021 · Paper III · Q10(a) (4 marks) · Oct 2024 · Paper III · Q10(b) (4 marks)
  10. Leprosy & pregnancy 3×Jun 2020 · Paper III · Q10(b) (4 marks) · Dec 2021 · Paper III · Q7(a) (4 marks) · Dec 2025 · Paper III · Q6(b) (5 marks)
  11. Pure neuritic leprosy 3×Jun 2021 · Paper III · Q9(a) (5 marks) · Jun 2022 · Paper III · Q1(a) (5 marks) · Jun 2025 · Paper III · Q2(a) (5 marks)
  12. Lazarine & autoaggressive leprosy 2×Dec 2021 · Paper III · Q9(c) (3 marks) · Jun 2025 · Paper III · Q7(c) (2 marks)
  13. Leprosy & HIV 1×Dec 2021 · Paper III · Q7(b) (3 marks)
  14. Indeterminate leprosy 1×Dec 2022 · Paper III · Q9(c) (2 marks)
  15. Serology & biomarkers (anti-PGL-1) 4×Jun 2022 · Paper III · Q2(a) (4 marks) · Apr 2023 · Paper III · Q7(a) (5 marks) · Oct 2024 · Paper III · Q6(b) (5 marks) · Jun 2025 · Paper III · Q1(b) (5 marks)
  16. Bacterial index & morphological index 3×Jun 2022 · Paper III · Q2(c) (3 marks) · Oct 2024 · Paper III · Q7(a) (2 marks) · Jun 2025 · Paper III · Q6(c) (3 marks)
  17. Nerve biopsy 2×Jun 2022 · Paper III · Q1(b) (5 marks) · Dec 2025 · Paper III · Q9(a) (5 marks)
  18. Histopathology of leprosy (TT vs LL) 1×Jun 2021 · Paper III · Q7(b) (3 marks)
  19. PCR in leprosy 1×Jun 2022 · Paper III · Q2(b) (3 marks)
  20. Slit-skin smear & AFB staining (incl. Fite stain) 1×May 2024 · Paper III · Q7 (10 marks)
Part 20 · Leprosy: Reactions, Neuritis, Treatment, Disability and Programme33 questions
  1. Thalidomide: role, adverse effects & monitoring 4×Dec 2020 · Paper III · Q8(a) (5 marks) · Dec 2021 · Paper III · Q6(b) (3 marks) · Dec 2022 · Paper III · Q7(b) (3 marks) · Dec 2025 · Paper III · Q7(b) (5 marks)
  2. ENL: pathogenesis, cytokines, investigations & management 4×Jun 2020 · Paper III · Q7 (10 marks) · Dec 2021 · Paper III · Q6(a) (3 marks) · Dec 2021 · Paper III · Q6(c) (4 marks) · May 2024 · Paper III · Q1(c) (4 marks)
  3. Recalcitrant / steroid-dependent ENL 3×Dec 2022 · Paper III · Q7(a) (4 marks) · Oct 2024 · Paper III · Q9(b) (5 marks) · Dec 2025 · Paper III · Q10(a) (5 marks)
  4. Type 1 (reversal/downgrading) reaction & differences between reactions 2×Dec 2021 · Paper III · Q9(a) (4 marks) · May 2024 · Paper III · Q1(b) (3 marks)
  5. ENL: systemic involvement in type 2 reaction 2×May 2024 · Paper III · Q1(a) (3 marks) · Dec 2025 · Paper III · Q7(a) (5 marks)
  6. Lucio phenomenon 1×Jun 2025 · Paper III · Q6(a) (3 marks)
  7. Nerve damage: classification & assessment (VMT, ST, SW filaments) 4×Dec 2021 · Paper III · Q10(c) (3 marks) · Dec 2022 · Paper III · Q3(c) (3 marks) · Apr 2023 · Paper III · Q6(b) (6 marks) · Jun 2025 · Paper III · Q1(a) (5 marks)
  8. Neuritis: diagnosis & management (incl. silent neuritis) 2×Jun 2021 · Paper III · Q9(b) (5 marks) · Dec 2022 · Paper III · Q3(b) (4 marks)
  9. Foot drop: differential diagnosis, investigations & treatment 2×Dec 2021 · Paper III · Q8(a) (3 marks) · Dec 2021 · Paper III · Q8(b) (4 marks)
  10. Nerve abscess 1×Apr 2023 · Paper III · Q6(a) (4 marks)
  11. Relapse in leprosy (definition, causes, diagnosis, relapse vs reaction) 5×Jun 2020 · Paper III · Q6 (10 marks) · Dec 2021 · Paper III · Q10(b) (3 marks) · Dec 2022 · Paper III · Q5(c) (3 marks) · Oct 2023 · Paper III · Q1 (10 marks) · Oct 2024 · Paper III · Q7(c) (6 marks)
  12. Dapsone hypersensitivity syndrome 2×Dec 2020 · Paper III · Q8(b) (5 marks) · Dec 2022 · Paper III · Q7(c) (3 marks)
  13. WHO MDT: current regimens, modifications & newer drugs 2×Dec 2020 · Paper III · Q10(b) (4 marks) · Oct 2023 · Paper III · Q3(b) (5 marks)
  14. Second-line anti-leprosy drugs (minocycline, clofazimine) 2×Dec 2021 · Paper III · Q9(b) (3 marks) · Jun 2025 · Paper III · Q6(b) (4 marks)
  15. Drug resistance in leprosy (MDR) 2×Apr 2023 · Paper III · Q7(b) (5 marks) · May 2024 · Paper III · Q8(a) (5 marks)
  16. Persisters in leprosy 2×Oct 2024 · Paper III · Q7(b) (2 marks) · Jun 2025 · Paper III · Q7(b) (3 marks)
  17. WHO MDT in special situations (defaulter, pregnancy, TB, HIV) 1×Jun 2025 · Paper III · Q5 (10 marks)
  18. Trophic ulcer, foot care & care of anaesthetic hands/feet 5×Jun 2020 · Paper III · Q9(a) (5 marks) · Jun 2022 · Paper III · Q10(c) (4 marks) · Dec 2022 · Paper III · Q1(a) (6 marks) · Dec 2022 · Paper III · Q9(a) (4 marks) · Oct 2024 · Paper III · Q8(b) (5 marks)
  19. Hand deformities (claw hand): enumeration & surgical management 3×Jun 2020 · Paper III · Q9(b) (5 marks) · Dec 2020 · Paper III · Q10(a) (6 marks) · May 2024 · Paper III · Q6(a) (4 marks)
  20. Facial deformities (leonine facies) & surgical correction 3×Dec 2020 · Paper III · Q7(a) (5 marks) · Dec 2022 · Paper III · Q1(b) (4 marks) · Dec 2025 · Paper III · Q8(a) (5 marks)
  21. MCR footwear 2×Dec 2020 · Paper III · Q6(a) (5 marks) · Dec 2021 · Paper III · Q8(c) (3 marks)
  22. WHO disability grading 2×Dec 2020 · Paper III · Q6(b) (5 marks) · Dec 2022 · Paper III · Q5(b) (3 marks)
  23. Splints & splinting 1×Dec 2022 · Paper III · Q5(a) (4 marks)
  24. Paralytic deformities 1×Apr 2023 · Paper III · Q3(b) (5 marks)
  25. Ocular leprosy 3×Dec 2022 · Paper III · Q9(b) (4 marks) · Oct 2024 · Paper III · Q8(a) (5 marks) · Jun 2025 · Paper III · Q4(b) (5 marks)
  26. Renal involvement 2×Apr 2023 · Paper III · Q3(a) (5 marks) · Jun 2025 · Paper III · Q4(a) (5 marks)
  27. Musculoskeletal involvement 1×Jun 2021 · Paper III · Q8(b) (7 marks)
  28. Systemic involvement in leprosy (overview) 1×Jun 2021 · Paper III · Q8(a) (3 marks)
  29. WHO Global Leprosy Strategy 2021 2030 & elimination targets 3×May 2024 · Paper III · Q6(c) (3 marks) · Oct 2024 · Paper III · Q9(a) (5 marks) · Oct 2024 · Paper III · Q10(a) (6 marks)
  30. Chemoprophylaxis (SDR-PEP) 2×Apr 2023 · Paper III · Q1(a) (4 marks) · May 2024 · Paper III · Q6(b) (3 marks)
  31. Leprosy vaccines (incl. LepVax) 2×Apr 2023 · Paper III · Q1(b) (6 marks) · Dec 2025 · Paper IV · Q3(b) (3 marks)
  32. Leprosy in India: current status & epidemiological indicators 2×Oct 2023 · Paper III · Q6(b) (5 marks) · Dec 2025 · Paper III · Q9(b) (5 marks)
  33. Leprosy-cured person 1×Dec 2022 · Paper III · Q3(a) (3 marks)
Part 21 · Dermatosurgery and Lasers18 questions
  1. Radiofrequency & electrosurgery 3×Jun 2022 · Paper I · Q6(c) (3 marks) · Jun 2022 · Paper IV · Q4(b) (3 marks) · Dec 2022 · Paper IV · Q7 (10 marks)
  2. Cryotherapy / cryosurgery 2×Dec 2020 · Paper IV · Q4(b) (5 marks) · Apr 2023 · Paper IV · Q4 (10 marks)
  3. Procedural dermatology: definition & classification 2×Jun 2022 · Paper IV · Q6(b) (3 marks) · May 2024 · Paper IV · Q5(a) (3 marks)
  4. Sutures & suturing techniques 5×Jun 2022 · Paper I · Q6(a) (3 marks) · Jun 2022 · Paper I · Q6(b) (4 marks) · May 2024 · Paper IV · Q4(a) (2 marks) · May 2024 · Paper IV · Q4(b) (2 marks) · May 2024 · Paper IV · Q4(c) (3 marks)
  5. Local anaesthesia: facial blocks, ring block, lignocaine toxicity 3×Dec 2021 · Paper I · Q8(a) (4 marks) · Dec 2021 · Paper I · Q8(b) (3 marks) · Dec 2021 · Paper I · Q8(c) (3 marks)
  6. Lasers in pigmentary disorders & picosecond laser 4×Dec 2021 · Paper IV · Q9(b) (3 marks) · Jun 2022 · Paper IV · Q3(b) (3 marks) · Oct 2023 · Paper IV · Q6(a) (5 marks) · Dec 2025 · Paper IV · Q7(a) (5 marks)
  7. Laser hair removal (diode vs Nd:YAG) 2×Jun 2020 · Paper IV · Q10(b) (5 marks) · May 2024 · Paper IV · Q1(b) (4 marks)
  8. Lasers for tattoo removal 2×Jun 2020 · Paper IV · Q10(a) (5 marks) · Jun 2025 · Paper IV · Q3(a) (5 marks)
  9. Lasers for vascular lesions 1×Dec 2021 · Paper IV · Q9(a) (4 marks)
  10. Ablative & fractional lasers 1×Jun 2022 · Paper IV · Q10(c) (4 marks)
  11. Principles of lasers 1×Oct 2024 · Paper IV · Q6(a) (5 marks)
  12. Microneedling / dermaroller 3×Dec 2020 · Paper IV · Q2(b) (5 marks) · Jun 2022 · Paper IV · Q4(c) (3 marks) · Dec 2022 · Paper IV · Q5(a) (3 marks)
  13. Microneedling radiofrequency (MNRF) 3×Dec 2021 · Paper IV · Q9(c) (3 marks) · Oct 2023 · Paper IV · Q6(b) (5 marks) · Dec 2025 · Paper IV · Q9(a) (5 marks)
  14. Acne scars: management (surgical & procedural) 3×Dec 2022 · Paper IV · Q1(b) (5 marks) · Apr 2023 · Paper IV · Q10(a) (6 marks) · Jun 2025 · Paper IV · Q10(b) (6 marks)
  15. Acne scars: classification 1×Dec 2020 · Paper IV · Q2(a) (5 marks)
  16. Keloids & hypertrophic scars: treatment options 3×Jun 2022 · Paper IV · Q3(a) (3 marks) · Apr 2023 · Paper IV · Q10(b) (4 marks) · May 2024 · Paper IV · Q6 (10 marks)
  17. Hair restoration surgery: evaluation & techniques (FUT/FUE) 7×Dec 2020 · Paper IV · Q5(b) (5 marks) · Dec 2021 · Paper IV · Q6(a) (4 marks) · Dec 2022 · Paper IV · Q5(c) (3 marks) · Dec 2022 · Paper IV · Q9(b) (5 marks) · Oct 2024 · Paper IV · Q9(a) (5 marks) · Jun 2025 · Paper IV · Q6(a) (6 marks) · Jun 2025 · Paper IV · Q6(b) (4 marks)
  18. Complications of hair transplantation 1×Apr 2023 · Paper IV · Q9(b) (4 marks)
Part 22 · Aesthetic Dermatology13 questions
  1. Botulinum toxin: mechanism & uses 3×Jun 2020 · Paper IV · Q8(a) (6 marks) · Dec 2021 · Paper IV · Q5(c) (3 marks) · Apr 2023 · Paper IV · Q2(b) (5 marks)
  2. Fillers: complications 2×Dec 2021 · Paper IV · Q7(c) (3 marks) · Apr 2023 · Paper IV · Q2(a) (5 marks)
  3. Chemical peels: classification & newer peels 3×Dec 2021 · Paper IV · Q6(c) (3 marks) · May 2024 · Paper IV · Q10(c) (3 marks) · Jun 2025 · Paper IV · Q3(b) (5 marks)
  4. Skin resurfacing (ablative methods) 2×Dec 2022 · Paper IV · Q9(a) (5 marks) · Apr 2023 · Paper IV · Q9(a) (6 marks)
  5. Facial rejuvenation (non-surgical) 2×May 2024 · Paper IV · Q10(b) (4 marks) · Oct 2024 · Paper IV · Q6(b) (5 marks)
  6. Platelet-rich plasma (PRP) 2×Dec 2020 · Paper IV · Q5(a) (5 marks) · Oct 2023 · Paper IV · Q10(a) (5 marks)
  7. Platelet-rich fibrin (PRF) 2×Jun 2022 · Paper IV · Q10(a) (3 marks) · May 2024 · Paper IV · Q1(c) (3 marks)
  8. Autologous fat transfer 1×Jun 2022 · Paper IV · Q10(b) (3 marks)
  9. Growth factors & exosomes in aesthetics 2×Jun 2025 · Paper IV · Q5(a) (5 marks) · Jun 2025 · Paper IV · Q5(b) (5 marks)
  10. Nail cosmetics & their adverse effects 2×Dec 2022 · Paper IV · Q6(c) (2 marks) · May 2024 · Paper I · Q5(b) (4 marks)
  11. Cosmetics & cosmeceuticals (cleansers, hair treatments) 2×Dec 2022 · Paper IV · Q6(a) (5 marks) · Dec 2022 · Paper IV · Q6(b) (3 marks)
  12. Phytochemicals & plant-derived products in cosmetic dermatology 1×Oct 2024 · Paper IV · Q7(b) (5 marks)
  13. Pitfalls in cosmetic dermatology 1×Oct 2024 · Paper IV · Q9(b) (5 marks)
Part 23 · Recent Advances: AI, Teledermatology and COVID-197 questions
  1. Artificial intelligence in dermatology 5×Jun 2020 · Paper IV · Q1(a) (5 marks) · Dec 2020 · Paper IV · Q9 (10 marks) · Jun 2022 · Paper IV · Q8(a) (4 marks) · Oct 2023 · Paper IV · Q1 (10 marks) · Jun 2025 · Paper IV · Q4 (10 marks)
  2. Teledermatology 2×Jun 2020 · Paper IV · Q1(b) (5 marks) · Jun 2022 · Paper IV · Q1(a) (4 marks)
  3. Cutaneous manifestations of COVID-19 2×Jun 2020 · Paper IV · Q3(a) (4 marks) · Jun 2022 · Paper IV · Q1(b) (6 marks)
  4. COVID-19: laboratory inflammatory markers 1×Jun 2021 · Paper I · Q4(a) (5 marks)
  5. Hand sanitizers 1×Jun 2021 · Paper IV · Q2(a) (5 marks)
  6. Online learning during COVID-19 1×Jun 2021 · Paper IV · Q2(b) (5 marks)
  7. Post-COVID opportunistic mycoses 1×Apr 2023 · Paper IV · Q8(a) (5 marks)

DNB Dermatology question papers, session by session

The topics set in each exam session, paper by paper and in question order, latest first.

DNB Dermatology December 202573 questions

Paper I

  • Q1 — Skin microbiome & normal flora (site-specific) 10 marks
  • Q2(a) — Toll-like receptors & innate immunity 5 marks
  • Q2(b) — Collagen synthesis 5 marks
  • Q3 — Skin as an endocrine organ 10 marks
  • Q4 — Wound healing: principles/stages, abnormal healing & newer therapies 10 marks
  • Q5(a) — Cutaneous stem cells: properties, types & role 5 marks
  • Q5(b) — Eumelanin & melanin types 5 marks
  • Q6 — Palisading granulomas 10 marks
  • Q7(a) — Itch: neurophysiology, mediators & anti-itch agents 6 marks
  • Q7(b) — Phototherapy: principles, dosing & NB-UVB 4 marks
  • Q8(a) — Grenz zone 5 marks
  • Q8(b) — Sunscreens & sun protection factor (SPF) 5 marks
  • Q9(a) — Spongiotic reaction pattern 5 marks
  • Q9(b) — Special stains (incl. PAS) in dermatopathology 5 marks
  • Q10(a) — Cutaneous mosaicism 5 marks
  • Q10(b) — Plasma cells 5 marks

Paper II

  • Q1 — Dexamethasone cyclophosphamide pulse (DCP) therapy 10 marks
  • Q2(a) — Lichenoid drug eruptions 6 marks
  • Q2(b) — Keratosis lichenoides chronica 4 marks
  • Q3(a) — Chronic spontaneous urticaria: investigations & management 4 marks
  • Q3(b) — Urticaria in pregnancy 3 marks
  • Q3(c) — Physical / inducible urticarias (incl. cholinergic) 3 marks
  • Q4 — Beh et's disease: mucocutaneous manifestations 10 marks
  • Q5(a) — SAPHO syndrome 5 marks
  • Q5(b) — Neutrophilic eccrine hidradenitis 5 marks
  • Q6(a) — Hirsutism & hyperandrogenism: causes, evaluation & treatment 6 marks
  • Q6(b) — Gram-negative folliculitis 4 marks
  • Q7 — Orofacial granulomatosis 10 marks
  • Q8(a) — Delusional parasitosis 5 marks
  • Q8(b) — Tuberculids (incl. papulonecrotic tuberculid) 5 marks
  • Q9(a) — Primary cicatricial alopecias: classification, LPP & FFA 5 marks
  • Q9(b) — Lupus panniculitis (lupus profundus) 5 marks
  • Q10(a) — Rosacea: subtypes & treatment 5 marks
  • Q10(b) — Calcinosis cutis 5 marks

Paper III

  • Q1(a) — Child sexual abuse, POCSO Act & STI evaluation in children 5 marks
  • Q1(b) — Complications of gonorrhoea 5 marks
  • Q2 — Anorectal STIs: proctitis, gay bowel syndrome, anorectal discharge 10 marks
  • Q3 — Syndromic case management: principles, advantages & limitations 10 marks
  • Q4(a) — Bowenoid papulosis 4 marks
  • Q4(b) — Chancre redux, serofast state & reinfection 3 marks
  • Q4(c) — Bacterial vaginosis: diagnosis (Amsel, Nugent, clue cells) & complications 3 marks
  • Q5(a) — Herpes in pregnancy & neonatal herpes 5 marks
  • Q5(b) — Herpes in pregnancy & neonatal herpes 5 marks
  • Q6(a) — Atypical presentations of leprosy 5 marks
  • Q6(b) — Leprosy & pregnancy 5 marks
  • Q7(a) — ENL: systemic involvement in type 2 reaction 5 marks
  • Q7(b) — Thalidomide: role, adverse effects & monitoring 5 marks
  • Q8(a) — Facial deformities (leonine facies) & surgical correction 5 marks
  • Q8(b) — Nodular lesions in leprosy: differential diagnosis 5 marks
  • Q9(a) — Nerve biopsy 5 marks
  • Q9(b) — Leprosy in India: current status & epidemiological indicators 5 marks
  • Q10(a) — Recalcitrant / steroid-dependent ENL 5 marks
  • Q10(b) — Venereophobia 5 marks

Paper IV

  • Q1(a) — Demodex & skin 5 marks
  • Q1(b) — Oral minoxidil 5 marks
  • Q2(a) — Nemolizumab (anti-IL-31) 5 marks
  • Q2(b) — JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis) 5 marks
  • Q3(a) — Antifibrotics: nintedanib & topical pirfenidone 3 marks
  • Q3(b) — Leprosy vaccines (incl. LepVax) 3 marks
  • Q3(c) — Cytolytic vaginitis 4 marks
  • Q4 — Air pollution & skin 10 marks
  • Q5(a) — Metabolic syndrome, obesity & acanthosis nigricans 5 marks
  • Q5(b) — mTOR inhibitors 5 marks
  • Q6(a) — Vaginal discharge: approach (incl. pregnancy & prepubertal girls) 5 marks
  • Q6(b) — Non-venereal genital ulcers & Lipschutz ulcer 5 marks
  • Q7(a) — Lasers in pigmentary disorders & picosecond laser 5 marks
  • Q7(b) — Recalcitrant dermatophytosis in India (incl. T. indotineae) 5 marks
  • Q8(a) — Skin lightening agents 5 marks
  • Q8(b) — STIs in men who have sex with men (MSM) 5 marks
  • Q9(a) — Microneedling radiofrequency (MNRF) 5 marks
  • Q9(b) — Drug-induced nail changes 5 marks
  • Q10(a) — Topical steroid misuse & topical steroid-dependent face 5 marks
  • Q10(b) — Apremilast & PDE4 inhibitors 5 marks
DNB Dermatology June 202582 questions

Paper I

  • Q1(a) — Langerhans cells, dendritic cells & antigen-presenting cells 5 marks
  • Q1(b) — Merkel cells 5 marks
  • Q2 — Skin biopsy: indications, techniques & fixatives 10 marks
  • Q3 — Primary & secondary skin lesions; configuration & distribution 10 marks
  • Q4(a) — Nail apparatus: diagram, development, parts & functions 3 marks
  • Q4(b) — Nail apparatus: diagram, development, parts & functions 3 marks
  • Q4(c) — Nail psoriasis & nail lichen planus 4 marks
  • Q5(a) — Systemic corticosteroids: regimens & indications 5 marks
  • Q5(b) — Topical corticosteroids: classification 5 marks
  • Q6(a) — Skin ageing: intrinsic & extrinsic 5 marks
  • Q6(b) — Premature ageing syndromes 5 marks
  • Q7(a) — Topical drug delivery: absorption, vehicles, enhancers & novel systems 4 marks
  • Q7(b) — Topical drug delivery: absorption, vehicles, enhancers & novel systems 3 marks
  • Q7(c) — Topical drug delivery: absorption, vehicles, enhancers & novel systems 3 marks
  • Q8(a) — Allergic vs irritant contact dermatitis 5 marks
  • Q8(b) — Patch test & photopatch test 5 marks
  • Q9(a) — Solar / UV spectrum, sources & measurement 5 marks
  • Q9(b) — Effects of UV radiation on skin 5 marks
  • Q10(a) — Iontophoresis 5 marks
  • Q10(b) — Intravenous immunoglobulin (IVIG) 5 marks

Paper II

  • Q1(a) — Gender & dermatology 5 marks
  • Q1(b) — Neonatal vesiculopustular & transient neonatal dermatoses 5 marks
  • Q2(a) — Dermoscopy of pigmentary disorders (incl. exogenous ochronosis) 6 marks
  • Q2(b) — Frictional melanosis & maturational hyperpigmentation 2 marks
  • Q2(c) — Frictional melanosis & maturational hyperpigmentation 2 marks
  • Q3 — Perioral, periorbital & scrotal dermatitis 10 marks
  • Q4(a) — Diet & dermatology (incl. acne) 5 marks
  • Q4(b) — Hormonal acne, hormonal therapy & PCOS 5 marks
  • Q5(a) — MDR / XDR tuberculosis 4 marks
  • Q5(b) — Cutaneous leishmaniasis: classification, diagnosis & treatment 6 marks
  • Q6 — Hidradenitis suppurativa: pathogenesis, staging, complications & management 10 marks
  • Q7(a) — IV drug abuse & nicotine: effects on skin 5 marks
  • Q7(b) — IV drug abuse & nicotine: effects on skin 5 marks
  • Q8 — Sweet syndrome & pyoderma gangrenosum: variants & associations 10 marks
  • Q9(a) — Angioedema without wheals: hereditary & drug-induced 4 marks
  • Q9(b) — Drug-induced autoimmune bullous diseases 6 marks
  • Q10(a) — Vasculitis vs vasculopathy; livedoid vasculopathy 3 marks
  • Q10(b) — Vasculitis vs vasculopathy; livedoid vasculopathy 4 marks
  • Q10(c) — Pigmented purpuric dermatosis (lichen aureus) 3 marks

Paper III

  • Q1(a) — Nerve damage: classification & assessment (VMT, ST, SW filaments) 5 marks
  • Q1(b) — Serology & biomarkers (anti-PGL-1) 5 marks
  • Q2(a) — Pure neuritic leprosy 5 marks
  • Q2(b) — Childhood leprosy 5 marks
  • Q3(a) — Bacterial vaginosis: diagnosis (Amsel, Nugent, clue cells) & complications 5 marks
  • Q3(b) — Syndromic management of vaginal discharge & cervicitis 5 marks
  • Q4(a) — Renal involvement 5 marks
  • Q4(b) — Ocular leprosy 5 marks
  • Q5 — WHO MDT in special situations (defaulter, pregnancy, TB, HIV) 10 marks
  • Q6(a) — Lucio phenomenon 3 marks
  • Q6(b) — Second-line anti-leprosy drugs (minocycline, clofazimine) 4 marks
  • Q6(c) — Bacterial index & morphological index 3 marks
  • Q7(a) — Anogenital warts: treatment (incl. persistent & paediatric) 5 marks
  • Q7(b) — Persisters in leprosy 3 marks
  • Q7(c) — Lazarine & autoaggressive leprosy 2 marks
  • Q8(a) — Mycoplasma genitalium & genital mycoplasmas 5 marks
  • Q8(b) — Vulvar pruritus & non-venereal vulvar dermatoses 5 marks
  • Q9(a) — Serological tests, reverse algorithm & monitoring of treatment 3 marks
  • Q9(b) — Congenital syphilis: clinical features, diagnosis & management 4 marks
  • Q9(c) — Jarisch Herxheimer reaction 3 marks
  • Q10(a) — Partner management in STIs 4 marks
  • Q10(b) — Child sexual abuse, POCSO Act & STI evaluation in children 6 marks

Paper IV

  • Q1 — JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis) 10 marks
  • Q2(a) — Doxy-PEP 3 marks
  • Q2(b) — PrEP & PEP for HIV 3 marks
  • Q2(c) — PrEP & PEP for HIV 4 marks
  • Q3(a) — Lasers for tattoo removal 5 marks
  • Q3(b) — Chemical peels: classification & newer peels 5 marks
  • Q4 — Artificial intelligence in dermatology 10 marks
  • Q5(a) — Growth factors & exosomes in aesthetics 5 marks
  • Q5(b) — Growth factors & exosomes in aesthetics 5 marks
  • Q6(a) — Hair restoration surgery: evaluation & techniques (FUT/FUE) 6 marks
  • Q6(b) — Hair restoration surgery: evaluation & techniques (FUT/FUE) 4 marks
  • Q7(a) — Berdazimer gel 3 marks
  • Q7(b) — Ozenoxacin 4 marks
  • Q7(c) — Anakinra (IL-1 blockade) 3 marks
  • Q8(a) — CAR T-cell therapy 5 marks
  • Q8(b) — Autologous serum therapy 5 marks
  • Q9(a) — Antiretroviral drugs: classification, targets & newer drugs 4 marks
  • Q9(b) — EGASP (Enhanced Gonococcal AMR Surveillance) 2 marks
  • Q9(c) — Bruton's tyrosine kinase (BTK) inhibitors 4 marks
  • Q10(a) — Ultraviolet-fluorescence dermoscopy 4 marks
  • Q10(b) — Acne scars: management (surgical & procedural) 6 marks
DNB Dermatology October 202481 questions

Paper I

  • Q1(a) — Sweat glands (eccrine & apocrine): structure & function 3 marks
  • Q1(b) — Sweat glands (eccrine & apocrine): structure & function 3 marks
  • Q1(c) — Fox Fordyce disease 4 marks
  • Q2 — Langerhans cells, dendritic cells & antigen-presenting cells 10 marks
  • Q3(a) — Heme biosynthesis pathway & classification of porphyrias 3 marks
  • Q3(b) — Cutaneous porphyrias (incl. PCT): clinical & histopathology 3 marks
  • Q3(c) — Cutaneous porphyrias (incl. PCT): clinical & histopathology 4 marks
  • Q4(a) — Hair follicle: longitudinal section (diagram) 5 marks
  • Q4(b) — Scalp biopsy in alopecias 5 marks
  • Q5(a) — Cutaneous tissue reaction patterns (overview) 6 marks
  • Q5(b) — Interface dermatitis & lichenoid tissue reaction 4 marks
  • Q6(a) — Antifungal drug resistance: mechanisms & testing 6 marks
  • Q6(b) — Pemphigus & AIBDs: target antigens & immunofluorescence 4 marks
  • Q7(a) — Raynaud's phenomenon & nailfold capillaroscopy 6 marks
  • Q7(b) — Sweat function tests 4 marks
  • Q8(a) — Itch: neurophysiology, mediators & anti-itch agents 5 marks
  • Q8(b) — Management of pruritus 5 marks
  • Q9(a) — Cutaneous tuberculosis: M. tuberculosis & pathogenesis of the spectrum 4 marks
  • Q9(b) — Cutaneous tuberculosis: M. tuberculosis & pathogenesis of the spectrum 6 marks
  • Q10(a) — Mast cells 3 marks
  • Q10(b) — Mastocytosis: classification & management 3 marks
  • Q10(c) — Telangiectasia macularis eruptiva perstans 4 marks

Paper II

  • Q1(a) — Classification of vasculitis (Chapel Hill) & approach 3 marks
  • Q1(b) — Classification of vasculitis (Chapel Hill) & approach 7 marks
  • Q2(a) — Lyme disease & erythema chronicum migrans 2 marks
  • Q2(b) — Lyme disease & erythema chronicum migrans 3 marks
  • Q2(c) — Annular & figurate erythemas 5 marks
  • Q3(a) — Urticaria: classification 3 marks
  • Q3(b) — Physical / inducible urticarias (incl. cholinergic) 3 marks
  • Q3(c) — Chronic spontaneous urticaria: investigations & management 4 marks
  • Q4(a) — Classification of psychodermatological disorders 4 marks
  • Q4(b) — Trichotillomania 6 marks
  • Q5(a) — Solar / UV spectrum, sources & measurement 2 marks
  • Q5(b) — Effects of UV radiation on skin 3 marks
  • Q5(c) — Bowen's disease & actinic keratosis 5 marks
  • Q6(a) — DRESS: diagnosis (RegiSCAR) & management 5 marks
  • Q6(b) — DRESS: diagnosis (RegiSCAR) & management 5 marks
  • Q7 — Ehlers Danlos syndrome 10 marks
  • Q8 — Rheumatoid arthritis & accelerated rheumatoid nodulosis 10 marks
  • Q9(a) — Panniculitis: classification 5 marks
  • Q9(b) — Lipodermatosclerosis 5 marks
  • Q10 — Chronic arsenic toxicity 10 marks

Paper III

  • Q1(a) — Normal flora / microbiome of female genital tract 3 marks
  • Q1(b) — Vaginal discharge: approach (incl. pregnancy & prepubertal girls) 7 marks
  • Q2(a) — Secondary syphilis & classification of syphilis 3 marks
  • Q2(b) — Congenital syphilis: clinical features, diagnosis & management 7 marks
  • Q3(a) — Persistent generalized lymphadenopathy 5 marks
  • Q3(b) — Anorectal STIs: proctitis, gay bowel syndrome, anorectal discharge 5 marks
  • Q4(a) — Non-gonococcal urethritis: aetiology & management 6 marks
  • Q4(b) — ART regimens (adult & paediatric) & monitoring 4 marks
  • Q5(a) — Molluscum contagiosum 4 marks
  • Q5(b) — Inguinal bubo: approach, syndromic management & chancroid vs LGV 6 marks
  • Q6(a) — Host factors, HLA & immune response in leprosy 5 marks
  • Q6(b) — Serology & biomarkers (anti-PGL-1) 5 marks
  • Q7(a) — Bacterial index & morphological index 2 marks
  • Q7(b) — Persisters in leprosy 2 marks
  • Q7(c) — Relapse in leprosy (definition, causes, diagnosis, relapse vs reaction) 6 marks
  • Q8(a) — Ocular leprosy 5 marks
  • Q8(b) — Trophic ulcer, foot care & care of anaesthetic hands/feet 5 marks
  • Q9(a) — WHO Global Leprosy Strategy 2021 2030 & elimination targets 5 marks
  • Q9(b) — Recalcitrant / steroid-dependent ENL 5 marks
  • Q10(a) — WHO Global Leprosy Strategy 2021 2030 & elimination targets 6 marks
  • Q10(b) — Histoid leprosy (clinical, diagnosis, histopathology) 4 marks

Paper IV

  • Q1(a) — Paraneoplastic dermatoses & cutaneous markers of internal malignancy 6 marks
  • Q1(b) — Cutaneous manifestations of cardiac disease 4 marks
  • Q2(a) — Psoriasis: molecular etiopathogenesis 5 marks
  • Q2(b) — Biologics in psoriasis 5 marks
  • Q3(a) — Atopic dermatitis: diagnostic criteria & severity scoring 5 marks
  • Q3(b) — Atopic dermatitis: management (severe/childhood, pruritus) 5 marks
  • Q4(a) — Non-melanoma skin cancer: risk factors, chemicals & genetic syndromes 3 marks
  • Q4(b) — Targeted therapy & immunotherapy in skin cancers 7 marks
  • Q5 — Autoantibodies & ANA in connective tissue diseases 10 marks
  • Q6(a) — Principles of lasers 5 marks
  • Q6(b) — Facial rejuvenation (non-surgical) 5 marks
  • Q7(a) — Ingrown toenail (onychocryptosis): surgical management 5 marks
  • Q7(b) — Phytochemicals & plant-derived products in cosmetic dermatology 5 marks
  • Q8(a) — Vascular malformations: classification 6 marks
  • Q8(b) — Infantile haemangioma: management 4 marks
  • Q9(a) — Hair restoration surgery: evaluation & techniques (FUT/FUE) 5 marks
  • Q9(b) — Pitfalls in cosmetic dermatology 5 marks
  • Q10 — Retinoids: classification, topical retinoids & prescribing guidelines 10 marks
DNB Dermatology May 202496 questions

Paper I

  • Q1(a) — Pruritus: clinical types & senile pruritus 2 marks
  • Q1(b) — Itch: neurophysiology, mediators & anti-itch agents 6 marks
  • Q1(c) — Pruritus: clinical types & senile pruritus 2 marks
  • Q2(a) — Regulatory T cells & resident memory T cells 5 marks
  • Q2(b) — Regulatory T cells & resident memory T cells 5 marks
  • Q3 — Skin ageing: intrinsic & extrinsic 10 marks
  • Q4 — Antimicrobial peptides 10 marks
  • Q5(a) — Nail apparatus: diagram, development, parts & functions 6 marks
  • Q5(b) — Nail cosmetics & their adverse effects 4 marks
  • Q6(a) — Interface dermatitis & lichenoid tissue reaction 6 marks
  • Q6(b) — Bowen's disease & actinic keratosis 4 marks
  • Q7(a) — Dermo-epidermal junction / basement membrane zone: labelled diagram 2 marks
  • Q7(b) — Epidermolysis bullosa acquisita 3 marks
  • Q7(c) — Prenatal diagnosis of genodermatoses 5 marks
  • Q8(a) — Melanogenesis & its regulation 6 marks
  • Q8(b) — Hypopigmented lesions in infancy: differential diagnosis 4 marks
  • Q9(a) — Non-scarring alopecias: classification 2 marks
  • Q9(b) — Trichoscopy of scarring alopecias (LPP, DLE) 4 marks
  • Q9(c) — Hair shaft disorders: enumeration 4 marks
  • Q10(a) — Skin as a thermoregulatory organ 4 marks
  • Q10(b) — Solar / UV spectrum, sources & measurement 3 marks
  • Q10(c) — Air pollution & skin 3 marks

Paper II

  • Q1(a) — Tuberculids (incl. papulonecrotic tuberculid) 6 marks
  • Q1(b) — Poxvirus infections (incl. mpox) 4 marks
  • Q2(a) — Rosacea: pathogenesis & histopathology 5 marks
  • Q2(b) — Epidermolysis bullosa pruriginosa 5 marks
  • Q3(a) — Langerhans cell histiocytosis & classification of histiocytoses 4 marks
  • Q3(b) — Heme biosynthesis pathway & classification of porphyrias 6 marks
  • Q4(a) — IgA vasculitis (Henoch Sch nlein purpura) 4 marks
  • Q4(b) — Dupilumab & biologics in atopic dermatitis 2 marks
  • Q4(c) — Annular & figurate erythemas 4 marks
  • Q5(a) — Perforating disorders (incl. reactive perforating collagenosis) 5 marks
  • Q5(b) — Cutaneous adverse effects of targeted anticancer therapy 5 marks
  • Q6(a) — Autoinflammatory disorders of skin 5 marks
  • Q6(b) — Autoinflammatory disorders of skin 3 marks
  • Q6(c) — Follicular occlusion tetrad 2 marks
  • Q7(a) — Vitiligo surgery (NCES, NCMT, acrofacial) 3 marks
  • Q7(b) — Melasma: aetiology, management & recent advances 3 marks
  • Q7(c) — Specific dermatoses of pregnancy 4 marks
  • Q8 — Mycetoma: classification, histopathology, diagnosis & management 10 marks
  • Q9(a) — Infantile haemangioma: management 5 marks
  • Q9(b) — Xeroderma pigmentosum 5 marks
  • Q10(a) — Sarcoidosis 3 marks
  • Q10(b) — Idiopathic & photoaggravated photodermatoses 4 marks
  • Q10(c) — Systemic lupus erythematosus: diagnosis, criteria & treatment 3 marks

Paper III

  • Q1(a) — ENL: systemic involvement in type 2 reaction 3 marks
  • Q1(b) — Type 1 (reversal/downgrading) reaction & differences between reactions 3 marks
  • Q1(c) — ENL: pathogenesis, cytokines, investigations & management 4 marks
  • Q2(a) — Neisseria gonorrhoeae: structure & gonococcal urethritis 4 marks
  • Q2(b) — PPNG & antimicrobial resistance in gonorrhoea 3 marks
  • Q2(c) — Complications of gonorrhoea 3 marks
  • Q3(a) — Recurrent genital herpes: suppressive therapy 3 marks
  • Q3(b) — Acyclovir-resistant / persistent genital herpes 3 marks
  • Q3(c) — Genital herpes: diagnosis (incl. type-specific serology) 4 marks
  • Q4(a) — Syndromic management of genital ulcer disease 4 marks
  • Q4(b) — Syndromic management of urethral discharge 3 marks
  • Q4(c) — Syndromic management of lower abdominal pain (PID) 3 marks
  • Q5 — Differentiating points across the leprosy spectrum (sub-polar LL, histoid, BT vs BB) 10 marks
  • Q6(a) — Hand deformities (claw hand): enumeration & surgical management 4 marks
  • Q6(b) — Chemoprophylaxis (SDR-PEP) 3 marks
  • Q6(c) — WHO Global Leprosy Strategy 2021 2030 & elimination targets 3 marks
  • Q7 — Slit-skin smear & AFB staining (incl. Fite stain) 10 marks
  • Q8(a) — Drug resistance in leprosy (MDR) 5 marks
  • Q8(b) — Vulvar pruritus & non-venereal vulvar dermatoses 5 marks
  • Q9(a) — Point-of-care tests for STIs 5 marks
  • Q9(b) — Anogenital warts: treatment (incl. persistent & paediatric) 5 marks
  • Q10(a) — Red scrotum 3 marks
  • Q10(b) — Bowenoid papulosis 3 marks
  • Q10(c) — Genital Crohn's disease 4 marks

Paper IV

  • Q1(a) — Confocal microscopy (reflectance / ex-vivo) 3 marks
  • Q1(b) — Laser hair removal (diode vs Nd:YAG) 4 marks
  • Q1(c) — Platelet-rich fibrin (PRF) 3 marks
  • Q2(a) — Lenalidomide 3 marks
  • Q2(b) — Opioid modulators: naltrexone & butorphanol 4 marks
  • Q2(c) — Opioid modulators: naltrexone & butorphanol 3 marks
  • Q3 — JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis) 10 marks
  • Q4(a) — Sutures & suturing techniques 2 marks
  • Q4(b) — Sutures & suturing techniques 2 marks
  • Q4(c) — Sutures & suturing techniques 3 marks
  • Q4(d) — Skin biopsy: indications, techniques & fixatives 3 marks
  • Q5(a) — Procedural dermatology: definition & classification 3 marks
  • Q5(b) — Immunohistochemistry in dermatology 4 marks
  • Q5(c) — Wood's lamp 3 marks
  • Q6 — Keloids & hypertrophic scars: treatment options 10 marks
  • Q7(a) — Skin substitutes in wound care 4 marks
  • Q7(b) — Gene therapy & gene editing 3 marks
  • Q7(c) — Onychoscopy (dermoscopy of onychomycosis) 3 marks
  • Q8(a) — Calcinosis cutis 3 marks
  • Q8(b) — Raynaud's phenomenon & nailfold capillaroscopy 3 marks
  • Q8(c) — Paraneoplastic dermatoses & cutaneous markers of internal malignancy 4 marks
  • Q9(a) — Stem cell based therapies 3 marks
  • Q9(b) — Drug-induced autoimmune bullous diseases 4 marks
  • Q9(c) — Paraneoplastic pemphigus 3 marks
  • Q10(a) — Warts: periungual & recalcitrant warts 3 marks
  • Q10(b) — Facial rejuvenation (non-surgical) 4 marks
  • Q10(c) — Chemical peels: classification & newer peels 3 marks
DNB Dermatology October 202371 questions

Paper I

  • Q1 — Sweat glands (eccrine & apocrine): structure & function 10 marks
  • Q2 — Skin barrier: structure, function & impaired barrier 10 marks
  • Q3 — Skin microbiome & normal flora (site-specific) 10 marks
  • Q4 — Itch: neurophysiology, mediators & anti-itch agents 10 marks
  • Q5(a) — Tzanck smear & cytodiagnosis 5 marks
  • Q5(b) — Immunohistochemistry in dermatology 5 marks
  • Q6 — Extracorporeal photopheresis 10 marks
  • Q7(a) — Autoantibodies & ANA in connective tissue diseases 5 marks
  • Q7(b) — Special stains (incl. PAS) in dermatopathology 5 marks
  • Q8(a) — Cutaneous mosaicism 5 marks
  • Q8(b) — Pigmentary demarcation lines & linear lesions 5 marks
  • Q9(a) — Dermo-epidermal junction / basement membrane zone: labelled diagram 5 marks
  • Q9(b) — Hair cycle (diagram) & factors affecting it 5 marks
  • Q10(a) — Interface dermatitis & lichenoid tissue reaction 5 marks
  • Q10(b) — Toll-like receptors & innate immunity 5 marks

Paper II

  • Q1(a) — Histopathology of scleroderma & scleromyxedema 5 marks
  • Q1(b) — Paraneoplastic pemphigus 5 marks
  • Q2(a) — Mycetoma: classification, histopathology, diagnosis & management 5 marks
  • Q2(b) — Post kala-azar dermal leishmaniasis (PKDL) 5 marks
  • Q3(a) — Dupilumab & biologics in atopic dermatitis 5 marks
  • Q3(b) — Systemic contact dermatitis 5 marks
  • Q4(a) — Sarcoidosis 5 marks
  • Q4(b) — Ichthyoses: classification, diagnostic clues & syndromic ichthyosis 5 marks
  • Q5(a) — Grenz zone 5 marks
  • Q5(b) — Lichen sclerosus (genital & extragenital) 5 marks
  • Q6(a) — Orofacial granulomatosis 5 marks
  • Q6(b) — Biofilms in skin disease 5 marks
  • Q7(a) — Trichoscopy of scarring alopecias (LPP, DLE) 5 marks
  • Q7(b) — Lupus panniculitis (lupus profundus) 5 marks
  • Q8(a) — Physiological skin changes in the newborn 5 marks
  • Q8(b) — Tuberculids (incl. papulonecrotic tuberculid) 5 marks
  • Q9 — Rosacea: subtypes & treatment 10 marks
  • Q10(a) — Atypical mycobacteria (swimming pool granuloma, NTM) 6 marks
  • Q10(b) — Kikuchi Fujimoto disease 4 marks

Paper III

  • Q1 — Relapse in leprosy (definition, causes, diagnosis, relapse vs reaction) 10 marks
  • Q2(a) — Complications of gonorrhoea 5 marks
  • Q2(b) — PPNG & antimicrobial resistance in gonorrhoea 5 marks
  • Q3(a) — STIs in men who have sex with men (MSM) 5 marks
  • Q3(b) — WHO MDT: current regimens, modifications & newer drugs 5 marks
  • Q4(a) — Child sexual abuse, POCSO Act & STI evaluation in children 5 marks
  • Q4(b) — Inguinal bubo: approach, syndromic management & chancroid vs LGV 5 marks
  • Q5(a) — HIV & other STIs: impact on GUD, herpes, chancroid, viral STIs 5 marks
  • Q5(b) — HIV & other STIs: impact on GUD, herpes, chancroid, viral STIs 5 marks
  • Q6(a) — Host factors, HLA & immune response in leprosy 5 marks
  • Q6(b) — Leprosy in India: current status & epidemiological indicators 5 marks
  • Q7(a) — PCR / NAAT in STIs 5 marks
  • Q7(b) — Biological false-positive VDRL 5 marks
  • Q8(a) — Vulvovaginal candidiasis (incl. complicated VVC) 5 marks
  • Q8(b) — DRESS: diagnosis (RegiSCAR) & management 5 marks
  • Q9(a) — Childhood leprosy 5 marks
  • Q9(b) — Atypical presentations of leprosy 5 marks
  • Q10(a) — Nodular lesions in leprosy: differential diagnosis 5 marks
  • Q10(b) — Non-venereal genital ulcers & Lipschutz ulcer 5 marks

Paper IV

  • Q1 — Artificial intelligence in dermatology 10 marks
  • Q2(a) — Herpes zoster: post-herpetic neuralgia & zoster vaccine 4 marks
  • Q2(b) — Antifungal drugs (topical & systemic azoles, naftifine) 3 marks
  • Q2(c) — Trifarotene 3 marks
  • Q3 — Sacroiliitis in dermatology 10 marks
  • Q4 — Ivermectin 10 marks
  • Q5 — ANCA-associated vasculitis (incl. polyangiitis) 10 marks
  • Q6(a) — Lasers in pigmentary disorders & picosecond laser 5 marks
  • Q6(b) — Microneedling radiofrequency (MNRF) 5 marks
  • Q7(a) — Antifibrotics: nintedanib & topical pirfenidone 4 marks
  • Q7(b) — IL-17 & IL-23 inhibitors (secukinumab, tildrakizumab) 3 marks
  • Q7(c) — Oral minoxidil 3 marks
  • Q8(a) — Bullous pemphigoid & its variants 5 marks
  • Q8(b) — Metabolic syndrome, obesity & acanthosis nigricans 5 marks
  • Q9(a) — Air pollution & skin 5 marks
  • Q9(b) — Basal cell carcinoma: pathogenesis, hedgehog pathway, topical agents & vismodegib 5 marks
  • Q10(a) — Platelet-rich plasma (PRP) 5 marks
  • Q10(b) — Pentoxifylline 5 marks
DNB Dermatology April 202377 questions

Paper I

  • Q1(a) — Hair cycle (diagram) & factors affecting it 5 marks
  • Q1(b) — Scalp biopsy in alopecias 5 marks
  • Q2(a) — Anatomy & physiology of lower-limb venous system 5 marks
  • Q2(b) — Warts: periungual & recalcitrant warts 5 marks
  • Q3(a) — Wound healing: principles/stages, abnormal healing & newer therapies 5 marks
  • Q3(b) — Wound healing: principles/stages, abnormal healing & newer therapies 5 marks
  • Q4(a) — Sunscreens & sun protection factor (SPF) 5 marks
  • Q4(b) — Antimalarials in dermatology 5 marks
  • Q5(a) — Seborrhoeic keratosis: histopathology 5 marks
  • Q5(b) — Immunohistochemical markers of histiocytoses 5 marks
  • Q6(a) — Poxvirus infections (incl. mpox) 5 marks
  • Q6(b) — Onychomycosis & non-dermatophyte moulds 5 marks
  • Q7(a) — Desmosomes, cell junctions & desmosomal diseases 5 marks
  • Q7(b) — Antifungal drug resistance: mechanisms & testing 5 marks
  • Q8(a) — Topical vehicles & fingertip unit 6 marks
  • Q8(b) — Topical vehicles & fingertip unit 4 marks
  • Q9(a) — Sensory innervation of hand & foot 5 marks
  • Q9(b) — Electron microscopy in skin diseases 5 marks
  • Q10(a) — Histopathology of non-infectious granulomas 4 marks
  • Q10(b) — Dermoscopy of lichen planus 6 marks

Paper II

  • Q1(a) — Pustular psoriasis 4 marks
  • Q1(b) — Psoriatic arthritis: classification (CASPAR) & management 6 marks
  • Q2 — Hirsutism & hyperandrogenism: causes, evaluation & treatment 10 marks
  • Q3(a) — Pemphigus & AIBDs: target antigens & immunofluorescence 5 marks
  • Q3(b) — Rituximab: uses & work-up 5 marks
  • Q4 — Systemic sclerosis: diagnosis, investigations, mRSS & management 10 marks
  • Q5(a) — Onycholysis 4 marks
  • Q5(b) — Injection therapy in nail disorders 6 marks
  • Q6(a) — Chronic arsenic toxicity 5 marks
  • Q6(b) — Tuberous sclerosis complex 5 marks
  • Q7 — Hidradenitis suppurativa: pathogenesis, staging, complications & management 10 marks
  • Q8(a) — Occupational & footwear contact dermatitis 5 marks
  • Q8(b) — Antifungal drugs (topical & systemic azoles, naftifine) 5 marks
  • Q9(a) — Phototherapy in vitiligo (NB-UVB, home phototherapy) 6 marks
  • Q9(b) — Extramammary Paget disease 4 marks
  • Q10(a) — Cutaneous larva migrans & myiasis 4 marks
  • Q10(b) — Cutaneous larva migrans & myiasis 3 marks
  • Q10(c) — Pediculosis: head lice & phthiriasis pubis 3 marks

Paper III

  • Q1(a) — Chemoprophylaxis (SDR-PEP) 4 marks
  • Q1(b) — Leprosy vaccines (incl. LepVax) 6 marks
  • Q2(a) — Buschke L wenstein tumour 4 marks
  • Q2(b) — HIV & other STIs: impact on GUD, herpes, chancroid, viral STIs 6 marks
  • Q3(a) — Renal involvement 5 marks
  • Q3(b) — Paralytic deformities 5 marks
  • Q4(a) — Cutaneous manifestations & opportunistic infections in HIV 5 marks
  • Q4(b) — Adverse effects of ART & their cutaneous manifestations 5 marks
  • Q5(a) — Herpes in pregnancy & neonatal herpes 4 marks
  • Q5(b) — ART regimens (adult & paediatric) & monitoring 6 marks
  • Q6(a) — Nerve abscess 4 marks
  • Q6(b) — Nerve damage: classification & assessment (VMT, ST, SW filaments) 6 marks
  • Q7(a) — Serology & biomarkers (anti-PGL-1) 5 marks
  • Q7(b) — Drug resistance in leprosy (MDR) 5 marks
  • Q8(a) — Congenital syphilis: clinical features, diagnosis & management 4 marks
  • Q8(b) — Prozone phenomenon 3 marks
  • Q8(c) — Lymphogranuloma venereum 3 marks
  • Q9(a) — Urethral discharge in men: approach & investigations 5 marks
  • Q9(b) — Non-gonococcal urethritis: aetiology & management 5 marks
  • Q10(a) — HIV testing: pre- & post-test counselling 5 marks
  • Q10(b) — Secondary syphilis & classification of syphilis 5 marks

Paper IV

  • Q1(a) — Cutaneous metastases 5 marks
  • Q1(b) — Mycosis fungoides (incl. hypopigmented MF) 5 marks
  • Q2(a) — Fillers: complications 5 marks
  • Q2(b) — Botulinum toxin: mechanism & uses 5 marks
  • Q3(a) — Systemic steroid adverse effects (osteoporosis) 6 marks
  • Q3(b) — Retinoids: monitoring & teratogenicity 4 marks
  • Q4 — Cryotherapy / cryosurgery 10 marks
  • Q5 — Erythroderma in children 10 marks
  • Q6(a) — Nail lacquers 4 marks
  • Q6(b) — Androgenetic alopecia & female pattern hair loss 6 marks
  • Q7(a) — SCARs: definition & classification 4 marks
  • Q7(b) — SJS/TEN: management & SCORTEN 6 marks
  • Q8(a) — Post-COVID opportunistic mycoses 5 marks
  • Q8(b) — Chikungunya 5 marks
  • Q9(a) — Skin resurfacing (ablative methods) 6 marks
  • Q9(b) — Complications of hair transplantation 4 marks
  • Q10(a) — Acne scars: management (surgical & procedural) 6 marks
  • Q10(b) — Keloids & hypertrophic scars: treatment options 4 marks
DNB Dermatology December 202295 questions

Paper I

  • Q1 — Desmosomes, cell junctions & desmosomal diseases 10 marks
  • Q2(a) — Dermoscopy of tumours (BCC, melanocytic lesions, vascular structures) 5 marks
  • Q2(b) — Dermoscopy of tumours (BCC, melanocytic lesions, vascular structures) 5 marks
  • Q3(a) — Muscles of facial expression & innervation 5 marks
  • Q3(b) — Antimicrobial peptides 3 marks
  • Q3(c) — MALDI-TOF MS in dermatophytes 2 marks
  • Q4(a) — Cutaneous stem cells: properties, types & role 4 marks
  • Q4(b) — Stem cell based therapies 3 marks
  • Q4(c) — Gene therapy & gene editing 3 marks
  • Q5(a) — Hair cycle (diagram) & factors affecting it 4 marks
  • Q5(b) — Hair keratins, hair colour & colouring agents 3 marks
  • Q5(c) — Hair keratins, hair colour & colouring agents 3 marks
  • Q6(a) — Skin biopsy: indications, techniques & fixatives 3 marks
  • Q6(b) — Intradermal tests 4 marks
  • Q6(c) — Wood's lamp 3 marks
  • Q7(a) — Dermal deposition disorders (histopathology) 4 marks
  • Q7(b) — Pseudoepitheliomatous & psoriasiform hyperplasia 3 marks
  • Q7(c) — Pseudoepitheliomatous & psoriasiform hyperplasia 3 marks
  • Q8(a) — Mechanisms of drug reactions & role of HLA 5 marks
  • Q8(b) — Antifungal drug resistance: mechanisms & testing 5 marks
  • Q9(a) — Heme biosynthesis pathway & classification of porphyrias 3 marks
  • Q9(b) — Cutaneous porphyrias (incl. PCT): clinical & histopathology 3 marks
  • Q9(c) — Physiological skin changes in pregnancy 4 marks
  • Q10(a) — Basic & advanced cardiac life support (BLS/ACLS) 4 marks
  • Q10(b) — Vitamin deficiencies & skin (water-soluble, vitamin A) 3 marks
  • Q10(c) — Zinc deficiency 3 marks

Paper II

  • Q1 — Non-melanoma skin cancer: risk factors, chemicals & genetic syndromes 10 marks
  • Q2 — Severity scoring in psoriasis (nail, pustular, PsA) 10 marks
  • Q3(a) — Ichthyoses: classification, diagnostic clues & syndromic ichthyosis 5 marks
  • Q3(b) — Ichthyoses: classification, diagnostic clues & syndromic ichthyosis 2 marks
  • Q3(c) — Collodion baby 3 marks
  • Q4 — Cutaneous manifestations of hepatitis B, hepatitis C & EBV 10 marks
  • Q5(a) — Sporotrichoid lesions: differential diagnosis 5 marks
  • Q5(b) — Neonatal vesiculopustular & transient neonatal dermatoses 5 marks
  • Q6(a) — Patch test & photopatch test 3 marks
  • Q6(b) — Idiopathic & photoaggravated photodermatoses 3 marks
  • Q6(c) — Phototherapy: principles, dosing & NB-UVB 4 marks
  • Q7(a) — Hirsutism & hyperandrogenism: causes, evaluation & treatment 5 marks
  • Q7(b) — Hormonal acne, hormonal therapy & PCOS 5 marks
  • Q8(a) — Long-term complications of EB 4 marks
  • Q8(b) — Pemphigus & AIBDs: target antigens & immunofluorescence 3 marks
  • Q8(c) — Dermatitis herpetiformis 3 marks
  • Q9(a) — Systemic sclerosis: diagnosis, investigations, mRSS & management 2 marks
  • Q9(b) — Atopic dermatitis: aetiology 2 marks
  • Q9(c) — Melasma: aetiology, management & recent advances 2 marks
  • Q9(d) — Vitiligo: aetiopathogenesis 2 marks
  • Q9(e) — Metabolic syndrome, obesity & acanthosis nigricans 2 marks
  • Q10(a) — Dermatomyositis (incl. amyopathic DM) 3 marks
  • Q10(b) — Autoantibodies & ANA in connective tissue diseases 3 marks
  • Q10(c) — Cutaneous amyloidosis 4 marks

Paper III

  • Q1(a) — Trophic ulcer, foot care & care of anaesthetic hands/feet 6 marks
  • Q1(b) — Facial deformities (leonine facies) & surgical correction 4 marks
  • Q2(a) — Mycoplasma genitalium & genital mycoplasmas 5 marks
  • Q2(b) — Congenital syphilis: clinical features, diagnosis & management 5 marks
  • Q3(a) — Leprosy-cured person 3 marks
  • Q3(b) — Neuritis: diagnosis & management (incl. silent neuritis) 4 marks
  • Q3(c) — Nerve damage: classification & assessment (VMT, ST, SW filaments) 3 marks
  • Q4(a) — Acyclovir-resistant / persistent genital herpes 5 marks
  • Q4(b) — Syndromic management of vaginal discharge & cervicitis 5 marks
  • Q5(a) — Splints & splinting 4 marks
  • Q5(b) — WHO disability grading 3 marks
  • Q5(c) — Relapse in leprosy (definition, causes, diagnosis, relapse vs reaction) 3 marks
  • Q6(a) — Structure & life cycle of HIV / retrovirus 5 marks
  • Q6(b) — Antiretroviral drugs: classification, targets & newer drugs 5 marks
  • Q7(a) — Recalcitrant / steroid-dependent ENL 4 marks
  • Q7(b) — Thalidomide: role, adverse effects & monitoring 3 marks
  • Q7(c) — Dapsone hypersensitivity syndrome 3 marks
  • Q8(a) — Bacterial vaginosis: diagnosis (Amsel, Nugent, clue cells) & complications 3 marks
  • Q8(b) — Bacterial vaginosis: diagnosis (Amsel, Nugent, clue cells) & complications 3 marks
  • Q8(c) — National AIDS Control Programme (NACP-V) 4 marks
  • Q9(a) — Trophic ulcer, foot care & care of anaesthetic hands/feet 4 marks
  • Q9(b) — Ocular leprosy 4 marks
  • Q9(c) — Indeterminate leprosy 2 marks
  • Q10(a) — HPV genotypes, clinical manifestations & HPV-related cancers 5 marks
  • Q10(b) — Adverse effects of ART & their cutaneous manifestations 5 marks

Paper IV

  • Q1(a) — Vitiligo surgery (NCES, NCMT, acrofacial) 5 marks
  • Q1(b) — Acne scars: management (surgical & procedural) 5 marks
  • Q2 — Hidradenitis suppurativa: pathogenesis, staging, complications & management 10 marks
  • Q3 — Chronic venous disease: evaluation, CEAP, sclerotherapy & compression 10 marks
  • Q4(a) — Hyperhidrosis: primary & management 5 marks
  • Q4(b) — Staphylococcal infections, SSSS & MRSA 5 marks
  • Q5(a) — Microneedling / dermaroller 3 marks
  • Q5(b) — Androgenetic alopecia & female pattern hair loss 4 marks
  • Q5(c) — Hair restoration surgery: evaluation & techniques (FUT/FUE) 3 marks
  • Q6(a) — Cosmetics & cosmeceuticals (cleansers, hair treatments) 5 marks
  • Q6(b) — Cosmetics & cosmeceuticals (cleansers, hair treatments) 3 marks
  • Q6(c) — Nail cosmetics & their adverse effects 2 marks
  • Q7 — Radiofrequency & electrosurgery 10 marks
  • Q8(a) — Apremilast & PDE4 inhibitors 3 marks
  • Q8(b) — JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis) 3 marks
  • Q8(c) — Antifungal drugs (topical & systemic azoles, naftifine) 4 marks
  • Q9(a) — Skin resurfacing (ablative methods) 5 marks
  • Q9(b) — Hair restoration surgery: evaluation & techniques (FUT/FUE) 5 marks
  • Q10(a) — Methotrexate (use & monitoring) 5 marks
  • Q10(b) — Retinoids: monitoring & teratogenicity 5 marks
DNB Dermatology June 202291 questions

Paper I

  • Q1 — Keratinization: keratins & cornified cell envelope 10 marks
  • Q2 — Wound healing: principles/stages, abnormal healing & newer therapies 10 marks
  • Q3 — Patterns of inheritance & genome sequencing 10 marks
  • Q4 — Dermis: cells, fibres & extracellular matrix 10 marks
  • Q5 — Cutaneous stem cells: properties, types & role 10 marks
  • Q6(a) — Sutures & suturing techniques 3 marks
  • Q6(b) — Sutures & suturing techniques 4 marks
  • Q6(c) — Radiofrequency & electrosurgery 3 marks
  • Q7 — Topical drug delivery: absorption, vehicles, enhancers & novel systems 10 marks
  • Q8 — Skin immune network: dendritic cells, mast cells & macrophages 10 marks
  • Q9(a) — Epidermal vs follicular melanocytes 3 marks
  • Q9(b) — Normal flora / microbiome of female genital tract 4 marks
  • Q9(c) — Cutaneous mosaicism 3 marks
  • Q10 — Primary & secondary skin lesions; configuration & distribution 10 marks

Paper II

  • Q1 — Scabies (incl. nodular scabies) 10 marks
  • Q2(a) — Atopic dermatitis: diagnostic criteria & severity scoring 4 marks
  • Q2(b) — Atopic dermatitis: management (severe/childhood, pruritus) 6 marks
  • Q3 — Systemic lupus erythematosus: diagnosis, criteria & treatment 10 marks
  • Q4(a) — Epidermolysis bullosa: pathogenesis & classification 3 marks
  • Q4(b) — Immunofluorescence mapping in EB 3 marks
  • Q4(c) — Kindler syndrome 4 marks
  • Q5 — Hidradenitis suppurativa: pathogenesis, staging, complications & management 10 marks
  • Q6(a) — Cutaneous amyloidosis 3 marks
  • Q6(b) — Lipodermatosclerosis 3 marks
  • Q6(c) — Scleromyxedema 4 marks
  • Q7(a) — Phototherapy in vitiligo (NB-UVB, home phototherapy) 3 marks
  • Q7(b) — Trichotillomania 3 marks
  • Q7(c) — Body dysmorphic disorder 4 marks
  • Q8(a) — Psoriatic arthritis: classification (CASPAR) & management 4 marks
  • Q8(b) — Angioedema without wheals: hereditary & drug-induced 3 marks
  • Q8(c) — Mastocytosis: classification & management 3 marks
  • Q9(a) — Occupational & footwear contact dermatitis 5 marks
  • Q9(b) — Recalcitrant dermatophytosis in India (incl. T. indotineae) 5 marks
  • Q10(a) — Red face 3 marks
  • Q10(b) — Systemic sclerosis: diagnosis, investigations, mRSS & management 4 marks
  • Q10(c) — Bacillary angiomatosis 3 marks

Paper III

  • Q1(a) — Pure neuritic leprosy 5 marks
  • Q1(b) — Nerve biopsy 5 marks
  • Q2(a) — Serology & biomarkers (anti-PGL-1) 4 marks
  • Q2(b) — PCR in leprosy 3 marks
  • Q2(c) — Bacterial index & morphological index 3 marks
  • Q3(a) — Syphilis in pregnancy 6 marks
  • Q3(b) — Congenital syphilis: clinical features, diagnosis & management 4 marks
  • Q4(a) — Mycoplasma genitalium & genital mycoplasmas 3 marks
  • Q4(b) — PPNG & antimicrobial resistance in gonorrhoea 4 marks
  • Q4(c) — Acyclovir-resistant / persistent genital herpes 3 marks
  • Q5(a) — Experimental leprosy & animal models 5 marks
  • Q5(b) — Animal models of syphilis 5 marks
  • Q6(a) — HPV genotypes, clinical manifestations & HPV-related cancers 3 marks
  • Q6(b) — Plasma cell balanitis 3 marks
  • Q6(c) — Lichen sclerosus (genital & extragenital) 4 marks
  • Q7(a) — HPV vaccines (incl. nonavalent) 3 marks
  • Q7(b) — Cutaneous manifestations & opportunistic infections in HIV 3 marks
  • Q7(c) — Lymphogranuloma venereum 4 marks
  • Q8(a) — Child sexual abuse, POCSO Act & STI evaluation in children 3 marks
  • Q8(b) — Child sexual abuse, POCSO Act & STI evaluation in children 4 marks
  • Q8(c) — Female genitalia: labelled diagram & Bartholin glands 3 marks
  • Q9(a) — Trichomoniasis: laboratory diagnosis 3 marks
  • Q9(b) — Bacterial vaginosis: diagnosis (Amsel, Nugent, clue cells) & complications 3 marks
  • Q9(c) — Vulvovaginal candidiasis (incl. complicated VVC) 4 marks
  • Q10(a) — Kaposi sarcoma 3 marks
  • Q10(b) — Serological tests, reverse algorithm & monitoring of treatment 3 marks
  • Q10(c) — Trophic ulcer, foot care & care of anaesthetic hands/feet 4 marks

Paper IV

  • Q1(a) — Teledermatology 4 marks
  • Q1(b) — Cutaneous manifestations of COVID-19 6 marks
  • Q2(a) — JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis) 3 marks
  • Q2(b) — Rituximab: uses & work-up 4 marks
  • Q2(c) — Vitiligo: newer & topical biologic treatments 3 marks
  • Q3(a) — Keloids & hypertrophic scars: treatment options 3 marks
  • Q3(b) — Lasers in pigmentary disorders & picosecond laser 3 marks
  • Q3(c) — Hair evaluation: hair pull test, trichogram 4 marks
  • Q4(a) — Vitiligo surgery (NCES, NCMT, acrofacial) 4 marks
  • Q4(b) — Radiofrequency & electrosurgery 3 marks
  • Q4(c) — Microneedling / dermaroller 3 marks
  • Q5(a) — CTCL: WHO-EORTC classification & variants 4 marks
  • Q5(b) — CTCL: immunohistochemistry 3 marks
  • Q5(c) — Pemphigus & AIBDs: target antigens & immunofluorescence 3 marks
  • Q6(a) — Infantile haemangioma: management 3 marks
  • Q6(b) — Procedural dermatology: definition & classification 3 marks
  • Q6(c) — Skin ageing: intrinsic & extrinsic 4 marks
  • Q7(a) — Impetigo herpetiformis (pustular psoriasis of pregnancy) 5 marks
  • Q7(b) — Ichthyoses: classification, diagnostic clues & syndromic ichthyosis 5 marks
  • Q8(a) — Artificial intelligence in dermatology 4 marks
  • Q8(b) — Melasma: aetiology, management & recent advances 3 marks
  • Q8(c) — Diet & dermatology (incl. acne) 3 marks
  • Q9(a) — Systematic review, meta-analysis, levels of evidence & EBM 2 marks
  • Q9(b) — Painful skin tumours 3 marks
  • Q9(c) — Ingrown toenail (onychocryptosis): surgical management 5 marks
  • Q10(a) — Platelet-rich fibrin (PRF) 3 marks
  • Q10(b) — Autologous fat transfer 3 marks
  • Q10(c) — Ablative & fractional lasers 4 marks
DNB Dermatology December 2021111 questions

Paper I

  • Q1 — Skin barrier: structure, function & impaired barrier 10 marks
  • Q2(a) — Nail apparatus: diagram, development, parts & functions 3 marks
  • Q2(b) — Nail signs: matrix changes & Beau's lines 4 marks
  • Q2(c) — Nail signs: matrix changes & Beau's lines 3 marks
  • Q3(a) — Autoantibodies & ANA in connective tissue diseases 4 marks
  • Q3(b) — Antiphospholipid syndrome / antibody 3 marks
  • Q3(c) — Autoantibodies & ANA in connective tissue diseases 3 marks
  • Q4(a) — Melanogenesis & its regulation 4 marks
  • Q4(b) — Epidermal melanin unit 3 marks
  • Q4(c) — Silvery hair syndromes 3 marks
  • Q5(a) — Skin microbiome & normal flora (site-specific) 4 marks
  • Q5(b) — Staphylococcal infections, SSSS & MRSA 3 marks
  • Q5(c) — Biofilms in skin disease 3 marks
  • Q6(a) — Female genitalia: labelled diagram & Bartholin glands 4 marks
  • Q6(b) — Female genitalia: labelled diagram & Bartholin glands 3 marks
  • Q6(c) — Vulvar pruritus & non-venereal vulvar dermatoses 3 marks
  • Q7(a) — Perforating disorders (incl. reactive perforating collagenosis) 6 marks
  • Q7(b) — Immunohistochemistry in dermatology 4 marks
  • Q8(a) — Local anaesthesia: facial blocks, ring block, lignocaine toxicity 4 marks
  • Q8(b) — Local anaesthesia: facial blocks, ring block, lignocaine toxicity 3 marks
  • Q8(c) — Local anaesthesia: facial blocks, ring block, lignocaine toxicity 3 marks
  • Q9(a) — Dermoscopy of tumours (BCC, melanocytic lesions, vascular structures) 4 marks
  • Q9(b) — Trichoscopy of tinea capitis 3 marks
  • Q9(c) — Dermoscopy of pigmentary disorders (incl. exogenous ochronosis) 3 marks
  • Q10(a) — Effects of UV radiation on skin 3 marks
  • Q10(b) — Xeroderma pigmentosum 4 marks
  • Q10(c) — Fitzpatrick skin phototypes 3 marks

Paper II

  • Q1 — Bullous pemphigoid & its variants 10 marks
  • Q2(a) — Autoinflammatory disorders of skin 3 marks
  • Q2(b) — Schnitzler syndrome 3 marks
  • Q2(c) — Kawasaki disease 4 marks
  • Q3(a) — Tuberculids (incl. papulonecrotic tuberculid) 4 marks
  • Q3(b) — MDR / XDR tuberculosis 3 marks
  • Q3(c) — Post kala-azar dermal leishmaniasis (PKDL) 3 marks
  • Q4(a) — Recalcitrant dermatophytosis in India (incl. T. indotineae) 3 marks
  • Q4(b) — Tinea capitis in children: treatment 3 marks
  • Q4(c) — Mycetoma: classification, histopathology, diagnosis & management 4 marks
  • Q5(a) — Hyperhidrosis: primary & management 3 marks
  • Q5(b) — Neonatal vesiculopustular & transient neonatal dermatoses 4 marks
  • Q5(c) — Collodion baby 3 marks
  • Q6 — Telogen effluvium (post-COVID) & diffuse hair loss 10 marks
  • Q7(a) — Urticarial vasculitis 3 marks
  • Q7(b) — IgA vasculitis (Henoch Sch nlein purpura) 4 marks
  • Q7(c) — ANCA-associated vasculitis (incl. polyangiitis) 3 marks
  • Q8(a) — Erythrodermic psoriasis (incl. children) 4 marks
  • Q8(b) — Childhood psoriasis 3 marks
  • Q8(c) — Psoriatic arthritis: classification (CASPAR) & management 3 marks
  • Q9(a) — Graft-versus-host disease 4 marks
  • Q9(b) — Scleredema 3 marks
  • Q9(c) — Eosinophilic fasciitis 3 marks
  • Q10(a) — SJS/TEN: management & SCORTEN 4 marks
  • Q10(b) — SDRIFE 3 marks
  • Q10(c) — DRESS: diagnosis (RegiSCAR) & management 3 marks

Paper III

  • Q1(a) — Genital ulcer disease: differential diagnosis & approach 4 marks
  • Q1(b) — Genital herpes: diagnosis (incl. type-specific serology) 4 marks
  • Q1(c) — Herpes in pregnancy & neonatal herpes 2 marks
  • Q2(a) — Vaginal discharge: approach (incl. pregnancy & prepubertal girls) 4 marks
  • Q2(b) — Syndromic management of vaginal discharge & cervicitis 3 marks
  • Q2(c) — PPNG & antimicrobial resistance in gonorrhoea 3 marks
  • Q3(a) — Urethral discharge in men: approach & investigations 4 marks
  • Q3(b) — Anorectal STIs: proctitis, gay bowel syndrome, anorectal discharge 3 marks
  • Q3(c) — Anorectal STIs: proctitis, gay bowel syndrome, anorectal discharge 3 marks
  • Q4(a) — PCR / NAAT in STIs 4 marks
  • Q4(b) — Biological false-positive VDRL 3 marks
  • Q4(c) — Prozone phenomenon 3 marks
  • Q5(a) — HIV & other STIs: impact on GUD, herpes, chancroid, viral STIs 4 marks
  • Q5(b) — HPV genotypes, clinical manifestations & HPV-related cancers 3 marks
  • Q5(c) — HPV vaccines (incl. nonavalent) 3 marks
  • Q6(a) — ENL: pathogenesis, cytokines, investigations & management 3 marks
  • Q6(b) — Thalidomide: role, adverse effects & monitoring 3 marks
  • Q6(c) — ENL: pathogenesis, cytokines, investigations & management 4 marks
  • Q7(a) — Leprosy & pregnancy 4 marks
  • Q7(b) — Leprosy & HIV 3 marks
  • Q7(c) — Childhood leprosy 3 marks
  • Q8(a) — Foot drop: differential diagnosis, investigations & treatment 3 marks
  • Q8(b) — Foot drop: differential diagnosis, investigations & treatment 4 marks
  • Q8(c) — MCR footwear 3 marks
  • Q9(a) — Type 1 (reversal/downgrading) reaction & differences between reactions 4 marks
  • Q9(b) — Second-line anti-leprosy drugs (minocycline, clofazimine) 3 marks
  • Q9(c) — Lazarine & autoaggressive leprosy 3 marks
  • Q10(a) — Histoid leprosy (clinical, diagnosis, histopathology) 4 marks
  • Q10(b) — Relapse in leprosy (definition, causes, diagnosis, relapse vs reaction) 3 marks
  • Q10(c) — Nerve damage: classification & assessment (VMT, ST, SW filaments) 3 marks

Paper IV

  • Q1(a) — Metabolic syndrome, obesity & acanthosis nigricans 4 marks
  • Q1(b) — Xanthomas & xanthelasma palpebrarum 4 marks
  • Q1(c) — Xanthomas & xanthelasma palpebrarum 2 marks
  • Q2(a) — Langerhans cell histiocytosis & classification of histiocytoses 4 marks
  • Q2(b) — Alkaptonuria 3 marks
  • Q2(c) — Cutaneous amyloidosis 3 marks
  • Q3 — Basal cell carcinoma: pathogenesis, hedgehog pathway, topical agents & vismodegib 10 marks
  • Q4(a) — Systematic review, meta-analysis, levels of evidence & EBM 4 marks
  • Q4(b) — Systematic review, meta-analysis, levels of evidence & EBM 3 marks
  • Q4(c) — Impact factor & Indian dermatology journals 3 marks
  • Q5(a) — Newer antihistamines 4 marks
  • Q5(b) — Apremilast & PDE4 inhibitors 3 marks
  • Q5(c) — Botulinum toxin: mechanism & uses 3 marks
  • Q6(a) — Hair restoration surgery: evaluation & techniques (FUT/FUE) 4 marks
  • Q6(b) — Vitiligo surgery (NCES, NCMT, acrofacial) 3 marks
  • Q6(c) — Chemical peels: classification & newer peels 3 marks
  • Q7(a) — Retinoids: classification, topical retinoids & prescribing guidelines 4 marks
  • Q7(b) — Topical amphotericin B 3 marks
  • Q7(c) — Fillers: complications 3 marks
  • Q8(a) — Trichotillomania 4 marks
  • Q8(b) — Body dysmorphic disorder 3 marks
  • Q8(c) — Vitiligo: psychosocial impact & counselling 3 marks
  • Q9(a) — Lasers for vascular lesions 4 marks
  • Q9(b) — Lasers in pigmentary disorders & picosecond laser 3 marks
  • Q9(c) — Microneedling radiofrequency (MNRF) 3 marks
  • Q10(a) — Leflunomide 3 marks
  • Q10(b) — IL-17 & IL-23 inhibitors (secukinumab, tildrakizumab) 4 marks
  • Q10(c) — Trifarotene 3 marks
DNB Dermatology June 202173 questions

Paper I

  • Q1(a) — Sweat glands (eccrine & apocrine): structure & function 3 marks
  • Q1(b) — Sweat function tests 2 marks
  • Q1(c) — Hyperhidrosis: primary & management 5 marks
  • Q2(a) — Toll-like receptors & innate immunity 5 marks
  • Q2(b) — Regulatory T cells & resident memory T cells 5 marks
  • Q3(a) — Desmosomes, cell junctions & desmosomal diseases 5 marks
  • Q3(b) — Stem cell based therapies 5 marks
  • Q4(a) — COVID-19: laboratory inflammatory markers 5 marks
  • Q4(b) — Wood's lamp 5 marks
  • Q5(a) — Nail psoriasis & nail lichen planus 6 marks
  • Q5(b) — Trichoscopy of alopecia areata 4 marks
  • Q6 — Keratinization: keratins & cornified cell envelope 10 marks
  • Q7(a) — Tzanck smear & cytodiagnosis 5 marks
  • Q7(b) — Special stains (incl. PAS) in dermatopathology 5 marks
  • Q8(a) — Skin microbiome & normal flora (site-specific) 5 marks
  • Q8(b) — Langerhans cells, dendritic cells & antigen-presenting cells 5 marks
  • Q9(a) — Epidermal melanin unit 5 marks
  • Q9(b) — Melanogenesis & its regulation 5 marks
  • Q10(a) — Nail apparatus: diagram, development, parts & functions 5 marks
  • Q10(b) — Nail apparatus: diagram, development, parts & functions 5 marks

Paper II

  • Q1(a) — Systemic contact dermatitis 5 marks
  • Q1(b) — Patch test & photopatch test 5 marks
  • Q2(a) — SCARs: definition & classification 3 marks
  • Q2(b) — DRESS: diagnosis (RegiSCAR) & management 7 marks
  • Q3(a) — Physical / inducible urticarias (incl. cholinergic) 5 marks
  • Q3(b) — Chronic spontaneous urticaria: investigations & management 5 marks
  • Q4(a) — Specific dermatoses of pregnancy 3 marks
  • Q4(b) — Pemphigoid gestationis 7 marks
  • Q5(a) — Rosacea: pathogenesis & histopathology 5 marks
  • Q5(b) — Rosacea: subtypes & treatment 5 marks
  • Q6(a) — Heme biosynthesis pathway & classification of porphyrias 3 marks
  • Q6(b) — Erythropoietic protoporphyria 7 marks
  • Q7(a) — Antiphospholipid syndrome / antibody 5 marks
  • Q7(b) — Pyogenic granuloma 5 marks
  • Q8(a) — Vitamin deficiencies & skin (water-soluble, vitamin A) 4 marks
  • Q8(b) — Pellagra 6 marks
  • Q9(a) — Hirsutism & hyperandrogenism: causes, evaluation & treatment 3 marks
  • Q9(b) — Hirsutism & hyperandrogenism: causes, evaluation & treatment 7 marks
  • Q10 — Mastocytosis: classification & management 10 marks

Paper III

  • Q1(a) — Structure & life cycle of HIV / retrovirus 4 marks
  • Q1(b) — Immune reconstitution inflammatory syndrome (IRIS) 6 marks
  • Q2(a) — HPV vaccines (incl. nonavalent) 5 marks
  • Q2(b) — Anogenital warts: treatment (incl. persistent & paediatric) 5 marks
  • Q3(a) — Complications of gonorrhoea 5 marks
  • Q3(b) — Arthritis associated with STIs 5 marks
  • Q4 — Bacterial vaginosis: diagnosis (Amsel, Nugent, clue cells) & complications 10 marks
  • Q5(a) — Jarisch Herxheimer reaction 5 marks
  • Q5(b) — Chancre redux, serofast state & reinfection 5 marks
  • Q6(a) — Host factors, HLA & immune response in leprosy 5 marks
  • Q6(b) — Lepromin test 5 marks
  • Q7(a) — Ridley Jopling classification 7 marks
  • Q7(b) — Histopathology of leprosy (TT vs LL) 3 marks
  • Q8(a) — Systemic involvement in leprosy (overview) 3 marks
  • Q8(b) — Musculoskeletal involvement 7 marks
  • Q9(a) — Pure neuritic leprosy 5 marks
  • Q9(b) — Neuritis: diagnosis & management (incl. silent neuritis) 5 marks
  • Q10 — Experimental leprosy & animal models 10 marks

Paper IV

  • Q1(a) — Ozenoxacin 3 marks
  • Q1(b) — Calamine lotion & gentian violet 3 marks
  • Q1(c) — Newer topical therapies for acne 4 marks
  • Q2(a) — Hand sanitizers 5 marks
  • Q2(b) — Online learning during COVID-19 5 marks
  • Q3(a) — Skin biopsy: indications, techniques & fixatives 4 marks
  • Q3(b) — Skin biopsy: indications, techniques & fixatives 6 marks
  • Q4 — Paraneoplastic dermatoses & cutaneous markers of internal malignancy 10 marks
  • Q5(a) — Atypical mycobacteria (swimming pool granuloma, NTM) 5 marks
  • Q5(b) — Staphylococcal infections, SSSS & MRSA 5 marks
  • Q6 — ANCA-associated vasculitis (incl. polyangiitis) 10 marks
  • Q7 — Cutaneous manifestations of endocrine (adrenal) disorders 10 marks
  • Q8 — Antioxidants in dermatology 10 marks
  • Q9 — Immunofluorescence: techniques & uses 10 marks
  • Q10(a) — Impact factor & Indian dermatology journals 5 marks
  • Q10(b) — High-frequency ultrasound 5 marks
DNB Dermatology December 202077 questions

Paper I

  • Q1(a) — Dermo-epidermal junction / basement membrane zone: labelled diagram 5 marks
  • Q1(b) — Subcorneal split disorders: differential diagnosis 5 marks
  • Q2 — Cutaneous stem cells: properties, types & role 10 marks
  • Q3 — Case-control vs cohort study, sample size & sampling methods 10 marks
  • Q4(a) — Histology of normal oral mucosa 4 marks
  • Q4(b) — Palisading granulomas 4 marks
  • Q4(c) — Rosacea: pathogenesis & histopathology 2 marks
  • Q5(a) — Skin as an endocrine organ 6 marks
  • Q5(b) — Vitamin D synthesis in skin 4 marks
  • Q6(a) — Antimicrobial peptides 3 marks
  • Q6(b) — Mast cells 3 marks
  • Q6(c) — Adhesion molecules 4 marks
  • Q7(a) — Itch: neurophysiology, mediators & anti-itch agents 6 marks
  • Q7(b) — Itch: neurophysiology, mediators & anti-itch agents 4 marks
  • Q8 — Wound healing: principles/stages, abnormal healing & newer therapies 10 marks
  • Q9(a) — Prenatal diagnosis of genodermatoses 4 marks
  • Q9(b) — Genodermatoses with photosensitivity 6 marks
  • Q10(a) — Trichoscopy in hair shaft disorders 4 marks
  • Q10(b) — Patch test & photopatch test 3 marks
  • Q10(c) — Hair evaluation: hair pull test, trichogram 3 marks

Paper II

  • Q1(a) — Palisading granulomas 4 marks
  • Q1(b) — Granuloma annulare 6 marks
  • Q2(a) — Dermatomyositis (incl. amyopathic DM) 4 marks
  • Q2(b) — Dermatomyositis (incl. amyopathic DM) 6 marks
  • Q3(a) — Facial hyperpigmentation: differential diagnosis 4 marks
  • Q3(b) — Melasma: aetiology, management & recent advances 6 marks
  • Q4(a) — Drug provocation test 5 marks
  • Q4(b) — SJS/TEN: management & SCORTEN 5 marks
  • Q5(a) — Classification of vasculitis (Chapel Hill) & approach 5 marks
  • Q5(b) — Chronic leg ulcer: investigation 5 marks
  • Q6(a) — Erythroderma in children 4 marks
  • Q6(b) — Erythrodermic psoriasis (incl. children) 6 marks
  • Q7(a) — Cutaneous amyloidosis 5 marks
  • Q7(b) — Xanthomas & xanthelasma palpebrarum 5 marks
  • Q8 — Specific dermatoses of pregnancy 10 marks
  • Q9(a) — Biologics in psoriasis 4 marks
  • Q9(b) — Methotrexate (use & monitoring) 6 marks
  • Q10(a) — Vitiligo: psychosocial impact & counselling 6 marks
  • Q10(b) — Vitiligo: psychosocial impact & counselling 4 marks

Paper III

  • Q1(a) — Syndromic management of lower abdominal pain (PID) 6 marks
  • Q1(b) — Syndromic management of lower abdominal pain (PID) 4 marks
  • Q2(a) — Pediculosis: head lice & phthiriasis pubis 5 marks
  • Q2(b) — Non-venereal genital ulcers & Lipschutz ulcer 5 marks
  • Q3 — Male genital tract: labelled diagram 10 marks
  • Q4(a) — Congenital syphilis: clinical features, diagnosis & management 5 marks
  • Q4(b) — Syphilis in pregnancy 5 marks
  • Q5(a) — Integrase inhibitors 5 marks
  • Q5(b) — PrEP & PEP for HIV 5 marks
  • Q6(a) — MCR footwear 5 marks
  • Q6(b) — WHO disability grading 5 marks
  • Q7(a) — Facial deformities (leonine facies) & surgical correction 5 marks
  • Q7(b) — Histoid leprosy (clinical, diagnosis, histopathology) 5 marks
  • Q8(a) — Thalidomide: role, adverse effects & monitoring 5 marks
  • Q8(b) — Dapsone hypersensitivity syndrome 5 marks
  • Q9 — Atypical presentations of leprosy 10 marks
  • Q10(a) — Hand deformities (claw hand): enumeration & surgical management 6 marks
  • Q10(b) — WHO MDT: current regimens, modifications & newer drugs 4 marks

Paper IV

  • Q1(a) — Hidradenitis suppurativa: pathogenesis, staging, complications & management 5 marks
  • Q1(b) — Infantile haemangioma: management 5 marks
  • Q2(a) — Acne scars: classification 5 marks
  • Q2(b) — Microneedling / dermaroller 5 marks
  • Q3(a) — JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis) 5 marks
  • Q3(b) — Calamine lotion & gentian violet 5 marks
  • Q4(a) — Herpes zoster: post-herpetic neuralgia & zoster vaccine 5 marks
  • Q4(b) — Cryotherapy / cryosurgery 5 marks
  • Q5(a) — Platelet-rich plasma (PRP) 5 marks
  • Q5(b) — Hair restoration surgery: evaluation & techniques (FUT/FUE) 5 marks
  • Q6(a) — Systemic corticosteroids: regimens & indications 5 marks
  • Q6(b) — Azathioprine 5 marks
  • Q7(a) — Quality-of-life indices (DLQI etc.) 5 marks
  • Q7(b) — Therapeutic paradox in dermatology 5 marks
  • Q8(a) — PASI & disease severity scoring indices 7 marks
  • Q8(b) — PASI & disease severity scoring indices 3 marks
  • Q9 — Artificial intelligence in dermatology 10 marks
  • Q10(a) — Dermoscopy of lichen planus 3 marks
  • Q10(b) — Dermoscopy of vitiligo 4 marks
  • Q10(c) — Dermoscopy of psoriasis 3 marks
DNB Dermatology June 202075 questions

Paper I

  • Q1(a) — Dermo-epidermal junction / basement membrane zone: labelled diagram 5 marks
  • Q1(b) — Epidermolysis bullosa: pathogenesis & classification 5 marks
  • Q2(a) — Hair cycle (diagram) & factors affecting it 5 marks
  • Q2(b) — Trichoscopy in hair shaft disorders 5 marks
  • Q3(a) — Dark field microscopy 5 marks
  • Q3(b) — Confocal microscopy (reflectance / ex-vivo) 5 marks
  • Q4 — Pilosebaceous unit, sebum composition & sebaceous gland disorders 10 marks
  • Q5(a) — Allergic contact dermatitis: pathophysiology 5 marks
  • Q5(b) — Non-eczematous forms of allergic contact dermatitis 5 marks
  • Q6 — Case-control vs cohort study, sample size & sampling methods 10 marks
  • Q7 — Koebner (isomorphic) phenomenon 10 marks
  • Q8 — Wound healing: principles/stages, abnormal healing & newer therapies 10 marks
  • Q9(a) — Interface dermatitis & lichenoid tissue reaction 6 marks
  • Q9(b) — Interface dermatitis & lichenoid tissue reaction 4 marks
  • Q10(a) — Cutaneous mosaicism 5 marks
  • Q10(b) — Pigmentary demarcation lines & linear lesions 5 marks

Paper II

  • Q1 — Cutaneous leishmaniasis: classification, diagnosis & treatment 10 marks
  • Q2(a) — Quality-of-life indices (DLQI etc.) 7 marks
  • Q2(b) — PASI & disease severity scoring indices 3 marks
  • Q3(a) — Warts: periungual & recalcitrant warts 4 marks
  • Q3(b) — Molluscum contagiosum 4 marks
  • Q3(c) — Alopecia areata 2 marks
  • Q4(a) — Impetigo herpetiformis (pustular psoriasis of pregnancy) 5 marks
  • Q4(b) — Pemphigoid gestationis 5 marks
  • Q5 — Porokeratosis 10 marks
  • Q6 — Angioedema without wheals: hereditary & drug-induced 10 marks
  • Q7 — Eczema herpeticum 10 marks
  • Q8(a) — Angiolymphoid hyperplasia with eosinophilia 5 marks
  • Q8(b) — Hypereosinophilic syndrome 5 marks
  • Q9(a) — Primary cicatricial alopecias: classification, LPP & FFA 5 marks
  • Q9(b) — Primary cicatricial alopecias: classification, LPP & FFA 5 marks
  • Q10(a) — Pseudolymphoma 2 marks
  • Q10(b) — Pseudolymphoma 3 marks
  • Q10(c) — CTCL: WHO-EORTC classification & variants 5 marks

Paper III

  • Q1(a) — Inguinal bubo: approach, syndromic management & chancroid vs LGV 5 marks
  • Q1(b) — Syndromic management of genital ulcer disease 5 marks
  • Q2 — Lymphogranuloma venereum 10 marks
  • Q3(a) — Antiretroviral drugs: classification, targets & newer drugs 6 marks
  • Q3(b) — Integrase inhibitors 4 marks
  • Q4(a) — Neisseria gonorrhoeae: structure & gonococcal urethritis 2 marks
  • Q4(b) — PPNG & antimicrobial resistance in gonorrhoea 4 marks
  • Q4(c) — Complications of gonorrhoea 4 marks
  • Q5(a) — Point-of-care tests for STIs 5 marks
  • Q5(b) — Congenital syphilis: clinical features, diagnosis & management 5 marks
  • Q6 — Relapse in leprosy (definition, causes, diagnosis, relapse vs reaction) 10 marks
  • Q7 — ENL: pathogenesis, cytokines, investigations & management 10 marks
  • Q8 — Histoid leprosy (clinical, diagnosis, histopathology) 10 marks
  • Q9(a) — Trophic ulcer, foot care & care of anaesthetic hands/feet 5 marks
  • Q9(b) — Hand deformities (claw hand): enumeration & surgical management 5 marks
  • Q10(a) — Childhood leprosy 3 marks
  • Q10(b) — Leprosy & pregnancy 4 marks
  • Q10(c) — Atypical presentations of leprosy 3 marks

Paper IV

  • Q1(a) — Artificial intelligence in dermatology 5 marks
  • Q1(b) — Teledermatology 5 marks
  • Q2(a) — Acne-related syndromes 5 marks
  • Q2(b) — Hormonal acne, hormonal therapy & PCOS 5 marks
  • Q3(a) — Cutaneous manifestations of COVID-19 4 marks
  • Q3(b) — Chikungunya 3 marks
  • Q3(c) — Dengue 3 marks
  • Q4(a) — Specific dermatoses of pregnancy 5 marks
  • Q4(b) — Zinc deficiency 5 marks
  • Q5(a) — Antiphospholipid syndrome / antibody 5 marks
  • Q5(b) — Melasma: aetiology, management & recent advances 5 marks
  • Q6(a) — Mechanisms of drug reactions & role of HLA 5 marks
  • Q6(b) — DRESS: diagnosis (RegiSCAR) & management 5 marks
  • Q7(a) — Air pollution & skin 4 marks
  • Q7(b) — Dermatoses at high altitude & in desert areas 3 marks
  • Q7(c) — Dermatoses at high altitude & in desert areas 3 marks
  • Q8(a) — Botulinum toxin: mechanism & uses 6 marks
  • Q8(b) — Dupilumab & biologics in atopic dermatitis 4 marks
  • Q9(a) — Cutaneous amyloidosis 4 marks
  • Q9(b) — Scabies (incl. nodular scabies) 3 marks
  • Q9(c) — Bullous pemphigoid & its variants 3 marks
  • Q10(a) — Lasers for tattoo removal 5 marks
  • Q10(b) — Laser hair removal (diode vs Nd:YAG) 5 marks

Read 18 solved answers free

The free 100-page sample is taken straight from the printed DNB Dermatology volumes, with the book's own page numbers. It contains:

  • The cover and complete index of all three volumes, with the papers and years each question was asked
  • Volume 1 answers: keratinisation, the dermo-epidermal junction and desmosomes, dermoscopy, and JAK inhibitors
  • Volume 2 answers: psoriasis, DRESS and SJS/TEN, and hidradenitis suppurativa
  • Volume 3 answers: congenital syphilis, ENL, WHO MDT regimens, and botulinum toxin and filler complications
Read the free sample (PDF)See the printed book
DNB Dermatology free sample, page 1DNB Dermatology free sample, page 4DNB Dermatology free sample, page 28DNB Dermatology free sample, page 82

Solved answers in the free sample

  1. Keratinization: keratins & cornified cell envelopeVolume 1 · Part 1
  2. Dermo-epidermal junction / basement membrane zone: labelled diagramVolume 1 · Part 1
  3. Desmosomes, cell junctions & desmosomal diseasesVolume 1 · Part 1
  4. Dermoscopy of lichen planusVolume 1 · Part 3
  5. Dermoscopy of pigmentary disorders (incl. exogenous ochronosis)Volume 1 · Part 3
  6. Dermoscopy of tumours (BCC, melanocytic lesions, vascular structures)Volume 1 · Part 3
  7. JAK inhibitors: mechanism, uses & adverse effects (AA, vitiligo, AD, psoriasis)Volume 1 · Part 5
  8. Psoriatic arthritis: classification (CASPAR) & managementVolume 2 · Part 7
  9. Biologics in psoriasisVolume 2 · Part 7
  10. Erythrodermic psoriasis (incl. children)Volume 2 · Part 7
  11. DRESS: diagnosis (RegiSCAR) & managementVolume 2 · Part 8
  12. SJS/TEN: management & SCORTENVolume 2 · Part 8
  13. Hidradenitis suppurativa: pathogenesis, staging, complications & managementVolume 2 · Part 11
  14. Congenital syphilis: clinical features, diagnosis & managementVolume 3 · Part 17
  15. ENL: pathogenesis, cytokines, investigations & managementVolume 3 · Part 20
  16. WHO MDT: current regimens, modifications & newer drugsVolume 3 · Part 20
  17. Botulinum toxin: mechanism & usesVolume 3 · Part 22
  18. Fillers: complicationsVolume 3 · Part 22

Frequently asked questions

How many DNB Dermatology previous-year questions are there?

This page lists 500 DNB Dermatology theory questions from 12 exam sessions, June 2020 to December 2025, arranged in 23 parts. Repeated questions are listed once, with every paper and year in which they were asked.

Which DNB Dermatology topics are asked most often?

Congenital syphilis: clinical features, diagnosis & management (7×); Hair restoration surgery: evaluation & techniques (FUT/FUE) (7×); Nail apparatus: diagram, development, parts & functions (6×); Wound healing: principles/stages, abnormal healing & newer therapies (6×); Itch: neurophysiology, mediators & anti-itch agents (6×).

Where can I find solved answers to these DNB Dermatology questions?

Every question on this page is answered in full in our printed DNB Dermatology, Venereology & Leprosy solved previous-year questions, written from Rook's Textbook of Dermatology 10e, the IADVL Textbook of Dermatology 5e and the IAL Textbook of Leprosy 3e.

Is there a free sample of the answers?

Yes. A free 100-page sample with full answers from the book is available: read the free sample (PDF).

How should I use these questions to prepare for the DNB Dermatology exam?

Start with the most-asked list, since repeated topics come back often. Then work through the topic-wise list part by part, and use the session-wise list to practise complete papers against the clock.

Get every answer in print

DNB Dermatology: 500 solved answers, printed, bound and delivered anywhere in India.

See the book